var title_f8_55_9072="Ankle deformity child";
var content_f8_55_9072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ankle fracture with obvious deformity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe clinical deformity in a 14-year-old boy with an ankle fracture. It is obvious without x-rays that internal rotation will be needed to reduce this fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cummings RJ. Distal tibial and fibular fractures. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_55_9072=[""].join("\n");
var outline_f8_55_9072=null;
var title_f8_55_9073="Chronic paronychia 2";
var content_f8_55_9073=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic paronychia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the swelling of the proximal nail fold, the loss of the cuticle, and the dystrophy of the nail plate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_55_9073=[""].join("\n");
var outline_f8_55_9073=null;
var title_f8_55_9074="Calculator: Gestational age from Estimated Date of Delivery (EDD)";
var content_f8_55_9074=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"GestationalAgeFromEDD_form\" name=\"GestationalAgeFromEDD_form\" onkeydown=\"clrResults();\" onkeyup=\"GestationalAgeFromEDD_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Gestational age from Estimated Date of Delivery (EDD)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Current Date",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\" nowrap=\"nowrap\">",
"             &nbsp;&nbsp;",
"             <select class=\"medCalcFontSelect\" name=\"current_month\" onchange=\"GestationalAgeFromEDD_fx();\">",
"              <option value=\"0\">",
"               Jan",
"              </option>",
"              <option value=\"1\">",
"               Feb",
"              </option>",
"              <option value=\"2\">",
"               Mar",
"              </option>",
"              <option value=\"3\">",
"               Apr",
"              </option>",
"              <option value=\"4\">",
"               May",
"              </option>",
"              <option value=\"5\">",
"               Jun",
"              </option>",
"              <option value=\"6\">",
"               Jul",
"              </option>",
"              <option value=\"7\">",
"               Aug",
"              </option>",
"              <option value=\"8\">",
"               Sep",
"              </option>",
"              <option value=\"9\">",
"               Oct",
"              </option>",
"              <option value=\"10\">",
"               Nov",
"              </option>",
"              <option value=\"11\">",
"               Dec",
"              </option>",
"              <option selected=\"selected\" value=\"-1\">",
"               MM",
"              </option>",
"             </select>",
"             <select class=\"medCalcFontSelect\" name=\"current_date\" onchange=\"GestationalAgeFromEDD_fx();\">",
"              <option value=\"1\">",
"               1",
"              </option>",
"              <option value=\"2\">",
"               2",
"              </option>",
"              <option value=\"3\">",
"               3",
"              </option>",
"              <option value=\"4\">",
"               4",
"              </option>",
"              <option value=\"5\">",
"               5",
"              </option>",
"              <option value=\"6\">",
"               6",
"              </option>",
"              <option value=\"7\">",
"               7",
"              </option>",
"              <option value=\"8\">",
"               8",
"              </option>",
"              <option value=\"9\">",
"               9",
"              </option>",
"              <option value=\"10\">",
"               10",
"              </option>",
"              <option value=\"11\">",
"               11",
"              </option>",
"              <option value=\"12\">",
"               12",
"              </option>",
"              <option value=\"13\">",
"               13",
"              </option>",
"              <option value=\"14\">",
"               14",
"              </option>",
"              <option value=\"15\">",
"               15",
"              </option>",
"              <option value=\"16\">",
"               16",
"              </option>",
"              <option value=\"17\">",
"               17",
"              </option>",
"              <option value=\"18\">",
"               18",
"              </option>",
"              <option value=\"19\">",
"               19",
"              </option>",
"              <option value=\"20\">",
"               20",
"              </option>",
"              <option value=\"21\">",
"               21",
"              </option>",
"              <option value=\"22\">",
"               22",
"              </option>",
"              <option value=\"23\">",
"               23",
"              </option>",
"              <option value=\"24\">",
"               24",
"              </option>",
"              <option value=\"25\">",
"               25",
"              </option>",
"              <option value=\"26\">",
"               26",
"              </option>",
"              <option value=\"27\">",
"               27",
"              </option>",
"              <option value=\"28\">",
"               28",
"              </option>",
"              <option value=\"29\">",
"               29",
"              </option>",
"              <option value=\"30\">",
"               30",
"              </option>",
"              <option value=\"31\">",
"               31",
"              </option>",
"              <option selected=\"selected\" value=\"-1\">",
"               DD",
"              </option>",
"             </select>",
"             <select class=\"medCalcFontSelect\" name=\"current_year\" onchange=\"GestationalAgeFromEDD_fx();\">",
"              <option value=\"2009\">",
"               2009",
"              </option>",
"              <option value=\"2010\">",
"               2010",
"              </option>",
"              <option value=\"2011\">",
"               2011",
"              </option>",
"              <option value=\"2012\">",
"               2012",
"              </option>",
"              <option value=\"2013\">",
"               2013",
"              </option>",
"              <option value=\"2014\">",
"               2014",
"              </option>",
"              <option value=\"2015\">",
"               2015",
"              </option>",
"              <option value=\"2016\">",
"               2016",
"              </option>",
"              <option value=\"2017\">",
"               2017",
"              </option>",
"              <option value=\"2018\">",
"               2018",
"              </option>",
"              <option value=\"2019\">",
"               2019",
"              </option>",
"              <option value=\"2020\">",
"               2020",
"              </option>",
"              <option value=\"2021\">",
"               2021",
"              </option>",
"              <option value=\"2022\">",
"               2022",
"              </option>",
"              <option value=\"2023\">",
"               2023",
"              </option>",
"              <option value=\"2024\">",
"               2024",
"              </option>",
"              <option value=\"2025\">",
"               2025",
"              </option>",
"              <option value=\"2026\">",
"               2026",
"              </option>",
"              <option value=\"2027\">",
"               2027",
"              </option>",
"              <option value=\"2028\">",
"               2028",
"              </option>",
"              <option value=\"2029\">",
"               2029",
"              </option>",
"              <option value=\"2030\">",
"               2030",
"              </option>",
"              <option selected=\"selected\" value=\"-1\">",
"               YYYY",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Estimated Date of Delivery",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\" nowrap=\"nowrap\">",
"             &nbsp;&nbsp;",
"             <select class=\"medCalcFontSelect\" name=\"edd_month\" onchange=\"GestationalAgeFromEDD_fx();\">",
"              <option value=\"0\">",
"               Jan",
"              </option>",
"              <option value=\"1\">",
"               Feb",
"              </option>",
"              <option value=\"2\">",
"               Mar",
"              </option>",
"              <option value=\"3\">",
"               Apr",
"              </option>",
"              <option value=\"4\">",
"               May",
"              </option>",
"              <option value=\"5\">",
"               Jun",
"              </option>",
"              <option value=\"6\">",
"               Jul",
"              </option>",
"              <option value=\"7\">",
"               Aug",
"              </option>",
"              <option value=\"8\">",
"               Sep",
"              </option>",
"              <option value=\"9\">",
"               Oct",
"              </option>",
"              <option value=\"10\">",
"               Nov",
"              </option>",
"              <option value=\"11\">",
"               Dec",
"              </option>",
"              <option selected=\"selected\" value=\"-1\">",
"               MM",
"              </option>",
"             </select>",
"             <select class=\"medCalcFontSelect\" name=\"edd_date\" onchange=\"GestationalAgeFromEDD_fx();\">",
"              <option value=\"1\">",
"               1",
"              </option>",
"              <option value=\"2\">",
"               2",
"              </option>",
"              <option value=\"3\">",
"               3",
"              </option>",
"              <option value=\"4\">",
"               4",
"              </option>",
"              <option value=\"5\">",
"               5",
"              </option>",
"              <option value=\"6\">",
"               6",
"              </option>",
"              <option value=\"7\">",
"               7",
"              </option>",
"              <option value=\"8\">",
"               8",
"              </option>",
"              <option value=\"9\">",
"               9",
"              </option>",
"              <option value=\"10\">",
"               10",
"              </option>",
"              <option value=\"11\">",
"               11",
"              </option>",
"              <option value=\"12\">",
"               12",
"              </option>",
"              <option value=\"13\">",
"               13",
"              </option>",
"              <option value=\"14\">",
"               14",
"              </option>",
"              <option value=\"15\">",
"               15",
"              </option>",
"              <option value=\"16\">",
"               16",
"              </option>",
"              <option value=\"17\">",
"               17",
"              </option>",
"              <option value=\"18\">",
"               18",
"              </option>",
"              <option value=\"19\">",
"               19",
"              </option>",
"              <option value=\"20\">",
"               20",
"              </option>",
"              <option value=\"21\">",
"               21",
"              </option>",
"              <option value=\"22\">",
"               22",
"              </option>",
"              <option value=\"23\">",
"               23",
"              </option>",
"              <option value=\"24\">",
"               24",
"              </option>",
"              <option value=\"25\">",
"               25",
"              </option>",
"              <option value=\"26\">",
"               26",
"              </option>",
"              <option value=\"27\">",
"               27",
"              </option>",
"              <option value=\"28\">",
"               28",
"              </option>",
"              <option value=\"29\">",
"               29",
"              </option>",
"              <option value=\"30\">",
"               30",
"              </option>",
"              <option value=\"31\">",
"               31",
"              </option>",
"              <option selected=\"selected\" value=\"-1\">",
"               DD",
"              </option>",
"             </select>",
"             <select class=\"medCalcFontSelect\" name=\"edd_year\" onchange=\"GestationalAgeFromEDD_fx();\">",
"              <option value=\"2009\">",
"               2009",
"              </option>",
"              <option value=\"2010\">",
"               2010",
"              </option>",
"              <option value=\"2011\">",
"               2011",
"              </option>",
"              <option value=\"2012\">",
"               2012",
"              </option>",
"              <option value=\"2013\">",
"               2013",
"              </option>",
"              <option value=\"2014\">",
"               2014",
"              </option>",
"              <option value=\"2015\">",
"               2015",
"              </option>",
"              <option value=\"2016\">",
"               2016",
"              </option>",
"              <option value=\"2017\">",
"               2017",
"              </option>",
"              <option value=\"2018\">",
"               2018",
"              </option>",
"              <option value=\"2019\">",
"               2019",
"              </option>",
"              <option value=\"2020\">",
"               2020",
"              </option>",
"              <option value=\"2021\">",
"               2021",
"              </option>",
"              <option value=\"2022\">",
"               2022",
"              </option>",
"              <option value=\"2023\">",
"               2023",
"              </option>",
"              <option value=\"2024\">",
"               2024",
"              </option>",
"              <option value=\"2025\">",
"               2025",
"              </option>",
"              <option value=\"2026\">",
"               2026",
"              </option>",
"              <option value=\"2027\">",
"               2027",
"              </option>",
"              <option value=\"2028\">",
"               2028",
"              </option>",
"              <option value=\"2029\">",
"               2029",
"              </option>",
"              <option value=\"2030\">",
"               2030",
"              </option>",
"              <option selected=\"selected\" value=\"-1\">",
"               YYYY",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Results:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Current Gestational Age by EDD",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input maxlength=\"16\" name=\"gest_edd\" onfocus=\"blur();\" size=\"16\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Mul T, Mongelli M, Gardosi J. A comparative analysis of second-trimester ultrasound dating formulae in pregnancies conceived with artificial reproductive techniques.",
"        <i>",
"         Ultrasound Obstet Gynecol",
"        </i>",
"        . 1996 Dec;8(6):397-402.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Westerway SC, Davison A, Cowell S. Ultrasonic fetal measurements: new Australian standards for the new millennium.",
"        <i>",
"         Aust N Z J Obstet Gynaecol",
"        </i>",
"        . 2000 Aug;40(3):297-302.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Altman DG, Chitty LS. New charts for ultrasound dating of pregnancy.",
"        <i>",
"         Ultrasound Obstet Gynecol",
"        </i>",
"        . 1997 Sep;10(3):174-91.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
"with(document.GestationalAgeFromEDD_form){",
"todaydatetime = new Date;",
"todaymonth = todaydatetime.getMonth();",
"todaydate = todaydatetime.getDate();",
"todayfullyear = todaydatetime.getFullYear();",
"",
"}",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_55_9074=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function GestationalAgeFromEDD_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.GestationalAgeFromEDD_form){",
"",
"",
"doCalc = true;",
"dp = 0;",
"monthname = new Array('Jan', 'Feb', 'Mar', 'Apr', 'May', 'Jun', 'Jul', 'Aug', 'Sep', 'Oct', 'Nov', 'Dec');",
"edd_time = new Date;",
"current_time = new Date;",
"var current_month_value = parseFloat(current_month.options[current_month.selectedIndex].value);",
"var current_date_value = parseFloat(current_date.options[current_date.selectedIndex].value);",
"var current_year_value = parseFloat(current_year.options[current_year.selectedIndex].value);",
"if ((current_month_value == 1) && (current_date_value > 28)){",
"if ((current_year_value % 4) == 0){ current_date_value = 29; current_date.selectedIndex = 28; }",
"else{ current_date_value = 28; current_date.selectedIndex = 27; };",
"}",
"if (((current_month_value == 3) || (current_month_value == 5) || (current_month_value == 8) || (current_month_value == 10)) && (current_date_value > 30)){ current_date_value = 30; current_date.selectedIndex = 29; };",
"current_time.setFullYear(current_year_value);",
"current_time.setMonth(current_month_value, current_date_value);",
"current_time.setHours(0);",
"var edd_month_value = parseFloat(edd_month.options[edd_month.selectedIndex].value);",
"var edd_date_value = parseFloat(edd_date.options[edd_date.selectedIndex].value);",
"var edd_year_value = parseFloat(edd_year.options[edd_year.selectedIndex].value);",
"if ((edd_month_value == 1) && (edd_date_value > 28)){",
"if ((edd_year_value % 4) == 0){ edd_date_value = 29; edd_date.selectedIndex = 28; }",
"else{ edd_date_value = 28; edd_date.selectedIndex = 27; };",
"}",
"if (((edd_month_value == 3) || (edd_month_value == 5) || (edd_month_value == 8) || (edd_month_value == 10)) && (edd_date_value > 30)){ edd_date_value = 30; edd_date.selectedIndex = 29; };",
"edd_time.setFullYear(edd_year_value);",
"edd_time.setMonth(edd_month_value, edd_date_value);",
"edd_time.setHours(0);",
"geddmillis = current_time.getTime() - edd_time.getTime() + 24192000000;",
"geddweeks = fixDP(geddmillis / 604800000, 1);",
"geddweeksfloor = Math.floor(geddweeks);",
"gedddays =  Math.round(7 * (geddweeks - geddweeksfloor));",
"daystxt = ' days';",
"if (gedddays == 1) daystxt = ' day';",
"if ((edd_year_value >= 0) && (edd_month_value >= 0) && (edd_date_value >= 0)){ gest_edd.value = geddweeksfloor + ' weeks' + ' ' + gedddays + daystxt;}",
"else { gest_edd.value = ''; }",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.GestationalAgeFromEDD_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.GestationalAgeFromEDD_form){",
"",
"gest_edd.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f8_55_9074=null;
var title_f8_55_9075="Paromomycin: Pediatric drug information";
var content_f8_55_9075=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Paromomycin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"    see \"Paromomycin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/49/7956?source=see_link\">",
"    see \"Paromomycin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F206519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humatin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Amebicide",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=see_link\">",
"      see \"Paromomycin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intestinal amebiasis (",
"     <i>",
"      Entamoeba histolytica",
"     </i>",
"     ): 25-35 mg/kg/day divided every 8 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dientamoeba fragilis",
"     </i>",
"     infection: 25-30 mg/kg/day divided every 8 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tapeworm:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      T. saginata",
"     </i>",
"     ,",
"     <i>",
"      T. solium",
"     </i>",
"     ,",
"     <i>",
"      D. latum",
"     </i>",
"     : 11 mg/kg/dose every 15 minutes for 4 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      H. nana",
"     </i>",
"     : 45 mg/kg/day once daily for 5-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intestinal amebiasis (",
"     <i>",
"      Entamoeba histolytica",
"     </i>",
"     ): 25-35 mg/kg/day divided every 8 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dientamoeba fragilis",
"     </i>",
"     infection: 25-30 mg/kg/day divided every 8 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tapeworm:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      T. saginata",
"     </i>",
"     ,",
"     <i>",
"      T. solium",
"     </i>",
"     ,",
"     <i>",
"      D. latum",
"     </i>",
"     : 1 g every 15 minutes for 4 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      H. nana",
"     </i>",
"     : 45 mg/kg/day once daily for 5-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic coma: 4 g/day in 2-4 divided doses for 5-6 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cryptosporidial diarrhea: 1.5-2 g/day in 3-4 divided doses for 10-14 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with or after meals",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute and chronic intestinal amebiasis due to susceptible",
"     <i>",
"      Entamoeba histolytica",
"     </i>",
"     (not effective in the treatment of extraintestinal amebiasis); tapeworm infestations; adjunctive management of hepatic coma; treatment of cryptosporidial diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F206545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, diarrhea, heartburn, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Eosinophilia, exanthema, headache, ototoxicity, pruritus, rash, secondary enterocolitis, steatorrhea, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to paromomycin or any component; intestinal obstruction",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired GI motility or possible or proven ulcerative bowel lesions; use with caution in patients with impaired renal function",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May result in overgrowth of nonsusceptible organisms",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F206502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1049157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Paromomycin may cause malabsorption of xylose, sucrose, and fats",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10236736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Paromomycin is poorly absorbed when given orally. Because it does not reach the maternal serum, it would not be expected to adversely affect the fetus. No adverse effects were observed in two infants whose mothers took paromomycin during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic urinalysis and renal function tests; be alert to ototoxicity",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acts directly on ameba in the intestinal lumen; interferes with bacterial protein synthesis by binding to 30S ribosomal subunit of susceptible bacteria",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Poor from the GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excreted unchanged in feces; portion of oral dose that may be absorbed is excreted in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/49/7956?source=see_link\">",
"      see \"Paromomycin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if ringing in ears, hearing loss, or dizziness occurs",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1049155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     With the treatment of cestodiasis caused by",
"     <i>",
"      T. solium",
"     </i>",
"     , paromomycin may cause disintegration of worm segments and release of viable eggs resulting in an increased risk for the development of cysticercosis",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Danziger LH, Kanyok TP, and Novak RM, &ldquo;Treatment of Cryptosporidial Diarrhea in an AIDS Patient With Paromomycin,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1993, 27(12):1460-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/55/9075/abstract-text/8305777/pubmed\" id=\"8305777\" target=\"_blank\">",
"        8305777",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu LX and Weller PF, &ldquo;Antiparasitic Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 334(18):1178-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/55/9075/abstract-text/8602186/pubmed\" id=\"8602186\" target=\"_blank\">",
"        8602186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12680 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.22.229.50-9BE3393297-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_55_9075=[""].join("\n");
var outline_f8_55_9075=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206519\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049148\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049142\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206506\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206493\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049151\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049150\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206545\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049154\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049141\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049140\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299825\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206502\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049157\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10236736\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049147\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049139\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049153\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049146\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049155\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12680\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12680|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16099?source=related_link\">",
"      Paromomycin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/49/7956?source=related_link\">",
"      Paromomycin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_55_9076="Polyethylene glycol 3350: Patient drug information";
var content_f8_55_9076=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Polyethylene glycol 3350: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/19/23860?source=see_link\">",
"     see \"Polyethylene glycol 3350: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/41/26260?source=see_link\">",
"     see \"Polyethylene glycol 3350: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2295346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dulcolax Balance&reg; [OTC];",
"     </li>",
"     <li>",
"      MiraLAX&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hard stools (constipation). It may take 2 to 4 days to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to polyethylene glycol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701354",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a block in the GI (gastrointestinal) tract.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696933",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug for more than 1 week unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bleeding from rectum or rectal pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694665",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Melt in 1 cup of water, juice, cola, or tea and drink it right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store powder at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11568 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7CC26F0507-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_55_9076=[""].join("\n");
var outline_f8_55_9076=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2295346\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023280\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023279\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023284\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023285\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023287\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023282\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023283\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023288\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023289\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/19/23860?source=related_link\">",
"      Polyethylene glycol 3350: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/41/26260?source=related_link\">",
"      Polyethylene glycol 3350: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_55_9077="Frovatriptan: Drug information";
var content_f8_55_9077=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Frovatriptan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/8/5253?source=see_link\">",
"    see \"Frovatriptan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F174639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Frova&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6761883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Frova&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F174656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimigraine Agent;",
"     </li>",
"     <li>",
"      Serotonin 5-HT",
"      <sub>",
"       1B, 1D",
"      </sub>",
"      Receptor Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F174641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Migraine:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     2.5 mg; if headache recurs, a second dose may be given if first dose provided relief and at least 2 hours have elapsed since the first dose (maximum daily dose: 7.5 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     2.5 mg; if headache recurs, a second dose may be given if first dose provided relief and at least 4 hours have elapsed since the first dose (maximum daily dose: 5 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     The safety of treating more than 4 migraines/month has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F174642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F174643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F174644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment necessary in mild-to-moderate hepatic impairment; use with caution in severe impairment (has not been studied in severe impairment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling",
"     </i>",
"     (not in U.S. labeling): Use is contraindicated in severe hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F174619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Frova&reg;: 2.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F174607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F174621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with fluids.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F174620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute treatment of migraine with or without aura",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14308802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term prevention of menstrually-associated migraines (MAMs)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3195082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Allegro: Brand name for frovatriptan [Germany], but also the brand name for  fluticasone [Israel]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Allegro [Germany] may be confused with Allegra and Allegra-D brand names for fexofenadine and fexofenadine/pseudoehedrine, respectively, in the [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F174654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing (4%), chest pain (2%), palpitation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (8%), fatigue (5%), headache (4%), hot or cold sensation (3%), somnolence (&ge;2%), anxiety (1%), dysesthesia (1%), hypoesthesia (1%), insomnia (1%), pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (3%), nausea (&ge;2%), dyspepsia (2%), abdominal pain (1%), diarrhea (1%), vomiting (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (4%), skeletal pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Vision abnormal (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (1%), sinusitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal dreaming, abnormal gait, abnormal lacrimation, abnormal reflexes, abnormal urine, agitation, amnesia, anorexia, arthralgia, arthrosis, ataxia, back pain, bowel changes, bradycardia, bullous eruption, cheilitis, concentration impaired, confusion, conjunctivitis, constipation, dehydration, depersonalization, depression, dysphagia, dyspnea, earache, ECG changes, emotional lability, epistaxis, eructation, esophagospasm, euphoria, eye pain, fever, flatulence, gastroesophageal reflux, hiccup, hot flushes, hyperacusis, hyperesthesia, hypertonia, hyperventilation, hypocalcemia, hypoglycemia, hypotonia, involuntary muscle contractions, laryngitis, leg cramps/pain, malaise, micturition, mouth edema, muscle weakness, myalgia, nervousness, nocturia, peptic ulcer, personality disorder, pharyngitis, polyuria, pruritus, purpura, renal pain, rigors, saliva increased, salivary gland pain, seizure, speech disorder, stomatitis, syncope, tachycardia, taste perversion, thirst, tongue paralysis, toothache, tremor, urinary frequency, vertigo, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F174624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to frovatriptan or any component of the formulation; patients with ischemic heart disease or signs or symptoms of ischemic heart disease (including Prinzmetal's angina, angina pectoris, myocardial infarction, silent myocardial ischemia); cerebrovascular syndromes (including strokes, transient ischemic attacks); peripheral vascular syndromes (including ischemic bowel disease); uncontrolled hypertension; use within 24 hours of ergotamine derivatives; use within 24 hours of another 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist; management of hemiplegic or basilar migraine",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Cardiac arrhythmias, valvular heart disease, congenital heart disease, atherosclerotic disease; management of ophthalmoplegic migraine; severe hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F174610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac events: Coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia/fibrillation, cardiac arrest, and death have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration. Patients who experience sensations of chest pain/pressure/tightness or symptoms suggestive of angina following dosing should be evaluated for coronary artery disease or Prinzmetal's angina before receiving additional doses; if dosing is resumed and similar symptoms recur, monitor with ECG.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular events: Cerebral/subarachnoid hemorrhage and stroke have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated blood pressure: Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vasospasm-related events: Peripheral vascular ischemia and colonic ischemia have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery disease: Should not be given to patients who have risk factors for CAD (eg, hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, menopause, male &gt;40 years of age) without adequate cardiac evaluation. Patients with suspected CAD should have cardiovascular evaluation to rule out CAD before considering use; if cardiovascular evaluation is &ldquo;satisfactory,&rdquo; first dose should be given in the healthcare provider's office (consider ECG monitoring). Periodic evaluation of cardiovascular status should be done in all patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurologic disease: Use with caution in patients with epilepsy and structural brain lesions; may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs (eg, SSRIs/SNRIs or triptans) or agents which reduce frovatriptan's metabolism. Concurrent use of serotonin precursors (eg, tryptophan) is not recommended.  If concomitant administration with SSRIs is warranted, monitor closely, especially at initiation and with dose increases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;18 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Only indicated for treatment of acute migraine; it is not indicated for migraine prophylaxis or for the treatment of cluster headaches. If a patient does not respond to the first dose, the diagnosis of migraine should be reconsidered; rule out underlying neurologic disease in patients with atypical headache, migraine (with no prior history of migraine) or inadequate clinical response to initial dosing.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F174650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F174614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F174636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food does not affect frovatriptan bioavailability.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F174616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F174626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies using frovatriptan in pregnant women. Use only if potential benefit to the mother outweighs the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F174647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16355503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if frovatriptan is excreted in breast milk. The manufacturer recommends that caution be exercised when administering frovatriptan to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F174625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Frova Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (9): $367.99",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Allegro (DE);",
"     </li>",
"     <li>",
"      Auradol (IT);",
"     </li>",
"     <li>",
"      Eumitan (AT);",
"     </li>",
"     <li>",
"      Forvey (ES);",
"     </li>",
"     <li>",
"      Fromen (CZ);",
"     </li>",
"     <li>",
"      Fromirex (NL);",
"     </li>",
"     <li>",
"      Frovex (IE);",
"     </li>",
"     <li>",
"      Menamig (CH);",
"     </li>",
"     <li>",
"      Menatriptan (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Migard (DK, EE, FI, GB, GR, NO, SE);",
"     </li>",
"     <li>",
"      Miguard (KP);",
"     </li>",
"     <li>",
"      Relieva (BG);",
"     </li>",
"     <li>",
"      Tigreat (FR, NO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F174609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective agonist for serotonin (5-HT",
"     <sub>",
"      1B",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      1D",
"     </sub>",
"     receptors) in cranial arteries; causes vasoconstriction and reduces sterile inflammation associated with antidromic neuronal transmission correlating with relief of migraine.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F174623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Male: 4.2 L/kg; Female: 3.0 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic via CYP1A2",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Male: ~20%; Female: ~30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~26 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (62%); urine (32%; &lt;10% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW and Shannon M, &ldquo;The Serotonin Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352:1112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/55/9077/abstract-text/15784664/pubmed\" id=\"15784664\" target=\"_blank\">",
"        15784664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rapoport A, Ryan R, Goldstein J, et al, &ldquo;Dose Range-Finding Studies With Frovatriptan in the Acute Treatment of Migraine,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 2002, 42(Suppl 2):74-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/55/9077/abstract-text/12028323/pubmed\" id=\"12028323\" target=\"_blank\">",
"        12028323",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ryan R, Geraud G, Goldstein J, et al, &ldquo;Clinical Efficacy of Frovatriptan: Placebo-Controlled Studies,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 2002, 42(Suppl 2):84-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/55/9077/abstract-text/12028324/pubmed\" id=\"12028324\" target=\"_blank\">",
"        12028324",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silberstein SD, Holland S, Freitag F, et al, &ldquo;Evidence-Based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults: Report of the Quality Standard Subcommittee of the American Academy of Neurology and the American Headache Society,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2012, 78(17):1337-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/55/9077/abstract-text/22529202/pubmed\" id=\"22529202\" target=\"_blank\">",
"        22529202",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8693 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-708A4DD6E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_55_9077=[""].join("\n");
var outline_f8_55_9077=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174639\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6761883\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174656\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174641\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174642\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174643\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174644\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174619\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174607\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174621\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174620\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14308802\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3195082\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174654\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174624\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174610\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174650\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174614\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174636\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174616\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174626\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174647\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16355503\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174625\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539866\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174609\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174623\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8693\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8693|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/8/5253?source=related_link\">",
"      Frovatriptan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_55_9078="Cyproterone and ethinyl estradiol: Patient drug information";
var content_f8_55_9078=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cyproterone and ethinyl estradiol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9576?source=see_link\">",
"     see \"Cyproterone and ethinyl estradiol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F155844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cyestra-35;",
"     </li>",
"     <li>",
"      Diane-35&reg;;",
"     </li>",
"     <li>",
"      Novo-Cyproterone/Ethinyl Estradiol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13213376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700856",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not smoke while taking birth control pills. Cigarette smoking raises the chance of very bad heart and blood-related side effects. This chance is higher with age (older than 35 years of age) and with heavy smoking (15 or more cigarettes per day). Birth control pills do not stop the spread of diseases caused by having sex.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pimples (acne).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701878",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cyproterone, ethinyl estradiol, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots, breast cancer, diseased arteries in the brain, disease of a heart valve with problems, endometrial cancer, heart disease, high blood pressure, liver disease, liver tumor, very bad headache, tumor where estrogen makes it grow, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703789",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have surgery and need bed rest.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701021",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a heavy smoker (more than 15 cigarettes per day) and older than 35 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have not started your period.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you turned yellow during pregnancy or with estrogen-based or hormone contraceptive use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697269",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high cholesterol, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have migraine headaches, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort, dong quai, black cohosh, saw palmetto, red clover, or ginseng with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking. People older than 35 years of age and/or smoking more than 15 cigarettes per day have more chance for heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Period (menstrual) changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallbladder disease, blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in how contact lenses feel in the eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698535",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you miss 2 periods in a row, take a pregnancy test before starting a new dosing cycle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696550",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Missed dosing facts may be found in the package insert or call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11712 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_55_9078=[""].join("\n");
var outline_f8_55_9078=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155844\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13213376\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026296\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026295\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026300\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026301\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026303\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026298\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026299\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026304\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026305\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9576?source=related_link\">",
"      Cyproterone and ethinyl estradiol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_55_9079="Compression bandaging for chronic venous insufficiency";
var content_f8_55_9079=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Compression bandaging for chronic venous insufficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/55/9079/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/55/9079/contributors\">",
"     David G. Armstrong, DPM, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/55/9079/contributors\">",
"     Andrew J Meyr, DPM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/55/9079/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/55/9079/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/55/9079/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/55/9079/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/55/9079/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/55/9079/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H442681058\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic venous insufficiency refers to the presence of edema, skin changes, or ulceration and represents advanced venous disease (CEAP 3 to 6). Chronic venous insufficiency (venous valvular reflux) is the most common cause of lower extremity ulceration, accounting for up to 80 percent of the approximately 2.5 million leg ulcer cases in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/1\">",
"     1",
"    </a>",
"    ]. Compression therapy remains the cornerstone of management for patients with venous ulceration. The goals of treatment are ulcer healing and reduction of edema, extent of lipodermatosclerosis and pain. Healing rates as high as 97 percent can be achieved in patients who are compliant [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/2\">",
"     2",
"    </a>",
"    ]. Compression bandaging systems are available as either inelastic or elastic compression bandages varying between one and four layers.",
"   </p>",
"   <p>",
"    Bandaging systems available for the treatment of lower extremity chronic venous insufficiency are reviewed. The epidemiology, classification, clinical presentation, diagnosis, pathophysiology, and other forms of medical management of chronic venous disease are discussed in an overview topic and separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link\">",
"     \"Overview and management of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H442681066\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compression bandages are indicated in patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant edema due to chronic venous insufficiency",
"     </li>",
"     <li>",
"      Weeping due to chronic venous insufficiency",
"     </li>",
"     <li>",
"      Lipodermatosclerosis &nbsp;",
"     </li>",
"     <li>",
"      Venous ulceration without cellulitis or significant pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H622447523\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to differentiate an ulcer due to chronic venous insufficiency from ischemic ulceration. In patients with non-palpable pulses or risk factors for peripheral artery disease, vascular evaluation including ankle-brachial index should be performed. Peripheral artery disease and chronic venous disease frequently coexist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/40/19078?source=see_link&amp;anchor=H55267256#H55267256\">",
"     \"Clinical assessment of wounds\", section on 'Differentiation of chronic ulcers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compression bandaging is contraindicated in patients found to have moderate to severe peripheral artery disease and used with great caution in patients with mild to moderate peripheral artery disease, as evidenced by an ankle-brachial index &lt;0.9 but &gt;0.6 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with abnormal ABIs or symptomatic PAD and venous ulcers should be referred to a vascular specialist for evaluation and decision-making regarding wound care, since compression therapy in patients with significant PAD may cause complications. The interpretation of noninvasive vascular studies and need for further noninvasive testing (eg, patients with diabetes) are discussed in detail elsewhere. (See",
"    <a class=\"local\" href=\"#H442681136\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with cellulitis and acute deep vein thrombosis should be treated to resolution prior to the use of compression therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link&amp;anchor=H6#H6\">",
"     \"Cellulitis and erysipelas\", section on 'Treatment'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H442681073\">",
"    <span class=\"h1\">",
"     BANDAGE TYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal pressure needed to overcome venous hypertension is not well defined. It is generally agreed that an external pressure of 35 to 40 mmHg at the ankle is necessary to prevent capillary exudation in legs affected by venous disease. Elastic or non-elastic compression bandages can be used to provide this level of pressure and treat chronic venous insufficiency.",
"   </p>",
"   <p>",
"    Compression bandages (single or multi-component) should be applied by trained personnel and changed by them once or twice a week depending upon the degree of drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intermittent pneumatic compression (IPC) therapy is another form of compression system that does not involve bandaging. IPC may benefit those patients who cannot tolerate continuous compression therapy and is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link&amp;anchor=H12#H12\">",
"     \"Medical management of lower extremity chronic venous disease\", section on 'Intermittent pneumatic compression therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H442681080\">",
"    <span class=\"h2\">",
"     Rigid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inelastic compression therapy provides a high working pressure with muscle contraction and therefore during ambulation, but no resting pressure. The degree of compression is not sustained and decreases over wear time [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Rigid bandages do not accommodate changes in leg volume if edema increases during prolonged standing or decreases when the legs are elevated. Frequent changes may be needed due to a malodorous accumulation of exudate from the ulcer &nbsp;",
"   </p>",
"   <p>",
"    The most common method of inelastic compression therapy is the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/14/23777?source=see_link\">",
"     Unna boot",
"    </a>",
"    which is an inelastic single component bandage [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/7\">",
"     7",
"    </a>",
"    ]. It is a moist bandage impregnated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    or calamine (with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/32/14852?source=see_link\">",
"     glycerin",
"    </a>",
"    ) that hardens after application. The Unna boot is relatively inexpensive and is available in several commercial preparations in either three or four inch widths. Unna boot is easy to apply and improves healing rates compared with placebo or hydroactive dressings [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H622445792\">",
"    <span class=\"h2\">",
"     Elastic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elastic compression can be provided to the lower extremity by one of several methods including elastic compression stockings, elastic wraps (eg, ACE), short stretch bandages (various manufacturers) or specialized multilayered bandaging systems. Elastic wraps are not generally used because they do not provide sufficient pressure. Graded compression stockings are often used in the treatment of chronic venous insufficiency typically following ulcer healing. The use and care of compression stockings are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link&amp;anchor=H7#H7\">",
"     \"Medical management of lower extremity chronic venous disease\", section on 'Graduated compression stockings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multilayered bandaging systems (eg, Profore) are usually composed of two or four layers usually consisting of at least one absorbent layer of wool or cotton wool (often the first layer next to the skin) and at least one elastic layer. Some systems omit the padding layer (eg, P&uuml;tter). The outermost layer adheres to the layer beneath to keep the bandage from slipping down. Unlike the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/14/23777?source=see_link\">",
"     Unna boot",
"    </a>",
"    , elastic compression bandaging systems conform to changes in leg size and thus sustain compression during activity and at rest. The bandaging system also includes absorptive layers which lessen the accumulation of fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H622447204\">",
"    <span class=\"h1\">",
"     CHOICE OF COMPRESSION BANDAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although nonelastic bandages are effective, a systematic review and metaanalysis of randomized trials found that adding a component of elastic compression therapy results in faster ulcer healing compared with inelastic compression therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/10\">",
"     10",
"    </a>",
"    ]. Venous leg ulcers in patients treated with four layer bandages heal faster, on average, than those of people treated with short stretch bandages [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Benefits were consistent across patients with differing prognostic profiles. In addition, high compression has been shown to be more effective than low compression, and multilayer bandages more effective than single layer [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The advantage of multi-layered elastic bandaging systems is better comfort and hence patient compliance and reduced overall expense due to improved ulcer healing rates [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/10,15,16\">",
"     10,15,16",
"    </a>",
"    ]. The main disadvantage of multi-component elastic compression bandaging systems is the degree of experience required for proper application. Although uncomfortable to wear, inelastic bandaging (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/14/23777?source=see_link\">",
"     Unna boot",
"    </a>",
"    ) is inexpensive and easy to apply and may be most useful during the initial phase of edema reduction, when bandages often require frequent changing due to excessive weeping [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/7\">",
"     7",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H442681115\">",
"    <span class=\"h1\">",
"     APPLICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any prior compression dressing is first removed with a dressing scissor, the skin is cleansed and the ulcer care performed as needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link&amp;anchor=H28#H28\">",
"     \"Medical management of lower extremity chronic venous disease\", section on 'Ulcer care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H622448135\">",
"    <span class=\"h2\">",
"     General tips for compression bandage placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compression bandage systems are wrapped around the leg from the foot to the proximal calf. The medial and lateral malleoli, tibial tuberosity and tibial crest may be more or less prominent depending upon the patient&rsquo;s body habitus. Compression of skin against these bony prominences may lead to ischemic changes in the skin if the bandage is wrapped too tight. In addition, nerve compression can occur where the nerves are more superficial. As an example, the dorsalis pedis artery and deep peroneal nerve cross the ankle and are superficial on the dorsum of the foot where they are prone to compression injury (",
"    <a class=\"graphic graphic_figure graphicRef51144 \" href=\"UTD.htm?21/56/22403\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A good compression bandage should tightly compress the leg on all sides and decrease in pressure from the distal to the proximal leg without constricting the leg. Depending upon the size and circumference of the leg, 3,4 or 5 inch wide (8, 10, 12 cm) bandages may be best suited for the leg. Tension on the bandage is most easily controlled with the rolled up part of the bandage above its free edge. Only in this manner is the bandage unrolled directly onto the leg (",
"    <a class=\"graphic graphic_figure graphicRef52239 \" href=\"UTD.htm?6/58/7074\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following tips apply to the placement of rigid and elastic compression bandages [",
"      <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The knee should be flexed at a right angle during bandaging to prevent congestion in the popliteal fossa",
"     </li>",
"     <li>",
"      Position the ankle joint in a neutral position (ie, right-angle) prior to applying the bandages and maintain this position (",
"      <a class=\"graphic graphic_figure graphicRef52239 \" href=\"UTD.htm?6/58/7074\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The compression bandage should start just distal to the metatarsal-phalangeal joint",
"     </li>",
"     <li>",
"      Any depressions (eg, perimalleolar region) should be padded with wadding to equalize pressure in the region",
"     </li>",
"     <li>",
"      The bandage should be unrolled directly onto the skin pulling evenly on both free edges in the direction of application",
"     </li>",
"     <li>",
"      Do not pull the bandage away from the leg",
"      <strong>",
"      </strong>",
"      because this tends to create folds in the bandage",
"     </li>",
"     <li>",
"      The heel must be included in the dressing",
"     </li>",
"     <li>",
"      At the knee, the bandage should include the head of the fibula",
"     </li>",
"     <li>",
"      Generally, bandage dressings have a better grip when subsequent layers are applied &ldquo;crosswise&rdquo;, over the prior layer as with the P&uuml;tter cross bandaging technique [",
"      <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A correctly applied bandage gives the patient the feeling of firm support but is relatively comfortable. Compression bandages achieve their full effectiveness in conjunction with active movement. Thus, if the patient walks around in the bandage, the treatment will be more successful [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H442681122\">",
"    <span class=\"h2\">",
"     Unna boot",
"    </span>",
"    &nbsp;&mdash;&nbsp;The application of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/14/23777?source=see_link\">",
"     Unna boot",
"    </a>",
"    begins at the metatarsal-phalangeal joint and ends just below the level of the tibial tuberosity. Failure to wrap the midfoot can lead to rapid accumulation of edema. Starting at the first metatarsal, the bandage is placed across the dorsum of the foot across the instep and around the plantar surface, then against the original starting point. Bandaging is continued with an upward slant overlapping the bandage one third to one half while moving proximally. A figure-of-eight turn is made around the ankle. A graded level of compression should be applied with the greatest amount of compression at the ankle with gradually less toward the knee. Avoid excessive pressure over any bony prominences or orthopedic foot deformities. Bandaging is continued up the leg overlapping each turn one third to one half of the width of the bandage up to the tibial tuberosity. The bandage can be cut and additional layers started again at the foot or the bandage loosely wrapped in two or three turns back to the foot level before wrapping the leg again. The standard length Unna bandage will typically wrap from foot to knee two or three times depending upon the diameter of the leg. For patients who have a larger extremity, a second bandage may be needed. An over-wrap of gauze can be applied to minimize soiling of the patient's garments. Additional general tips for the application of compression bandages are listed above. (See",
"    <a class=\"local\" href=\"#H622448135\">",
"     'General tips for compression bandage placement'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H442681129\">",
"    <span class=\"h2\">",
"     Multilayer compression bandages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The level of compression achieved during the placement of flat, elastic compression bandages is determined by the physical and elastomeric properties of the fabric, the size and shape of the limb, and the skill or technique of the clinician in providing the proper level of tension in the bandage fabric during its placement [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/4\">",
"     4",
"    </a>",
"    ]. If the tension, and therefore pressure, is too low, the bandage will be ineffective, but if the pressure is too high then, as with the rigid bandage, there is a potential for tissue ischemia and necrosis. [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/12\">",
"     12",
"    </a>",
"    ]. Elastic bandage layers are also applied starting at the base of the toes. Failure to apply proper tension over the foot can lead to rapid accumulation of edema over the dorsum of the foot. The layers of the bandaging system are briefly discussed below. Additional general tips for the application of compression bandages are listed above. (See",
"    <a class=\"local\" href=\"#H622448135\">",
"     'General tips for compression bandage placement'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H622445806\">",
"    <span class=\"h3\">",
"     Padding (layer 1)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The padding layer should cover all vulnerable areas and should protrude from beneath the other layers at the toes and proximal leg to provide protection from the edge of the bandage. Padding provides a layer of material to protect areas at risk for pressure necrosis such as the tibial crest, metatarsal bones, medial and lateral malleoli and Achilles tendon.",
"   </p>",
"   <p>",
"    The tibial crest is vulnerable to high levels of pressure and ischemic skin necrosis, particularly in individuals with thin limbs, and is often unnoticed until the bandage is removed. Simple methods such as pleating the padding or the addition of a strip of wool over the area can provide extra protection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/18\">",
"     18",
"    </a>",
"    ]. Extra padding should also be used in those who have orthopedic foot deformities such as hallux valgus (bunion) to prevent potential compression injury.",
"   </p>",
"   <p>",
"    In patients who are prone to eczematous skin change, a light tubular cotton bandage can be applied next to the skin before placement of the wool layer. Patients with lymphedematous changes of the toes can be managed by first bandaging the toes with a light, mildly extensible cotton bandage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H622445813\">",
"    <span class=\"h3\">",
"     Crepe bandage (layer 2)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The crepe bandage provides extra absorbency and smooths down the wool layer prior to placement of the outer elastic bandages. This layer adds little to the compressive effect of the bandaging system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H622445820\">",
"    <span class=\"h3\">",
"     Extensible elastic bandage (layer 3)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extensible elastic bandage layer is the first of two elastic bandages layers. The material provides a sub-bandage pressure of approximately 17 mmHg when applied at 50 percent extension with a 50 percent overlap using a figure-of-eight technique [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. In champagne-bottle-shaped limbs, the figure-of-eight application can be widened to improve the conformability of the bandage. If more pressure is required over an edematous calf, the following techniques can be used [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increase bandage extension &gt;50 percent",
"     </li>",
"     <li>",
"      Increasing overlap &gt;50 percent",
"     </li>",
"     <li>",
"      Add an additional elastic bandage layer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, in patients with thin limbs, pressure can be reduced by decreasing bandage extension &lt;50 percent. The wide extensibility curve (ability to stretch) of these bandages allows a degree of flexibility during their application, but again the clinician must take care not to decrease the pressure to an ineffective level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H622445827\">",
"    <span class=\"h3\">",
"     Cohesive elastic bandage (layer 4)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cohesive elastic bandage provides a greater level of compression (sub-bandage pressure approximately 23 mmHg), and thus, it must not be over-extended [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/18\">",
"     18",
"    </a>",
"    ]. It is a frequent misconception that this layer simply maintains the bandage in position. This layer of bandaging should extend over the upper portion of the gastrocnemius muscle to prevent slippage with care not to excessively compress in the region of the superficial peroneal nerve (",
"    <a class=\"graphic graphic_figure graphicRef51144 \" href=\"UTD.htm?21/56/22403\">",
"     figure 1",
"    </a>",
"    ). The cohesive layer should not contact the skin directly due to the potential for development of latex allergy. Latex-free outer layer systems are available. The two outer elastic bandages, when used in combination, provide a sub-bandage pressure of approximately 40 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H622447437\">",
"    <span class=\"h1\">",
"     PATIENT INSTRUCTIONS AND FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should be instructed to elevate the affected extremity when seated and avoid prolonged standing [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9079/abstract/3\">",
"     3",
"    </a>",
"    ]. The patient may complain of pain initially following placement of the compression bandage but the pain should subside. If pain increases or new pain is experienced that is not alleviated with elevation, or there is discoloration or numbness of the foot or toes, the bandage should be removed immediately.",
"   </p>",
"   <p>",
"    The patient should be advised to keep the dressing dry; a plastic bag can be placed over the leg when showering.",
"   </p>",
"   <p>",
"    The patient should return to have the compression bandage changed once or twice per week. If there is excessive drainage or foul odor, the patient should be instructed to return to have the dressing changed; more frequent dressing changes up to three times a week may be needed until drainage is controlled.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H442681136\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the complications associated with compression bandaging are avoidable. Symptoms and signs of lower extremity ischemia can develop if the bandage is applied too tightly. Patients should be instructed to remove the bandage if numbness, tingling or discoloration of the toes occurs and to seek medical attention if the symptoms do not immediately resolve. (See",
"    <a class=\"local\" href=\"#H622447437\">",
"     'Patient instructions and follow-up'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Excessive pressure over the instep and bony prominences of the leg and foot can cause skin necrosis. Additional padding prior to bandaging will alleviate pressure points. (See",
"    <a class=\"local\" href=\"#H622448135\">",
"     'General tips for compression bandage placement'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Accumulation of exudate from the ulcer under compression dressings can lead to foul odor and predispose to fungal infection. If the bandage becomes soaked, all occlusive and compressive dressings should be removed and any fungal rash treated to resolution before reapplication. Increasing the frequency of bandaging may help to manage the drainage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link&amp;anchor=H23#H23\">",
"     \"Dermatophyte (tinea) infections\", section on 'Tinea corporis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Contact dermatitis can develop from one of the components in the bandaging system in susceptible individuals (eg, zinc in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/14/23777?source=see_link\">",
"     Unna boot",
"    </a>",
"    , latex in elastic wraps). Latex free elastic wraps are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link&amp;anchor=H33#H33\">",
"     \"Medical management of lower extremity chronic venous disease\", section on 'Contact Dermatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/47/41714?source=see_link\">",
"       \"Patient information: Varicose veins and other vein disease in the legs (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/47/41714?source=see_link\">",
"       \"Patient information: Varicose veins and other vein disease in the legs (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H442681185\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compression bandages are indicated to manage the complications of lower extremity chronic venous disease including significant edema, weeping, lipodermatosclerosis and venous ulceration. Compression therapy is the primary treatment for patients with venous ulceration with high rates of healing achieved in patients who are compliant with the therapy. (See",
"      <a class=\"local\" href=\"#H442681058\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H442681066\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compression bandaging is contraindicated in patients with peripheral artery disease, cellulitis and acute deep vein thrombosis. Noninvasive arterial studies should be performed on patients with weak or nonpalpable pulses and lower extremity ulcer or those with risk factors for atherosclerosis. Cellulitis and deep vein thrombosis should be treated to resolution prior to placement of compression bandages. (See",
"      <a class=\"local\" href=\"#H622447523\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several types of compression bandages are available for the treatment of lower extremity chronic venous disease and are generally divided into rigid and elastic compression. Either is capable of providing the 35 to 40 mmHg of pressure needed to achieve healing of venous ulcers; however, elastic bandages are more effective in maintaining pressure when the patient is not moving. The most common type of rigid bandage is the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/14/23777?source=see_link\">",
"       Unna boot",
"      </a>",
"      , which is a single-component bandage. Multilayer bandaging systems are composed of two to four layers of various materials of which at least one layer is elastic. (See",
"      <a class=\"local\" href=\"#H442681073\">",
"       'Bandage types'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest elastic multilayered compression bandages rather than nonelastic single layer bandages for the treatment of ulceration associated with chronic venous insufficiency (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Although multilayered compression bandages are more costly, elastic compression therapy results in faster ulcer healing compared with inelastic compression therapy and overall costs associated with treatment may be reduced. Elastic bandaging systems are also associated with better patient compliance due to increased comfort. Inelastic bandages may be useful during the initial phase of edema reduction, when bandages require frequent changing due to excessive weeping. (See",
"      <a class=\"local\" href=\"#H622447204\">",
"       'Choice of compression bandage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compression bandage systems are wrapped around the leg from the foot to the proximal calf. Care is taken to avoid excessive compression of skin against any bony prominences. Walking is needed to achieve the full compressive effect of the bandage. (See",
"      <a class=\"local\" href=\"#H442681115\">",
"       'Application'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of compression bandaging are avoided with proper application. If the patient complains of excessive pain following placement or new pain is experienced that is not alleviated with elevation, or there is discoloration or numbness of the foot or toes, the bandage should be removed immediately. If the symptoms do not resolve with bandage removal, the patient should seek immediate medical attention. (See",
"      <a class=\"local\" href=\"#H442681115\">",
"       'Application'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H622447437\">",
"       'Patient instructions and follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9079/abstract/1\">",
"      Brem H, Kirsner RS, Falanga V. Protocol for the successful treatment of venous ulcers. Am J Surg 2004; 188:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9079/abstract/2\">",
"      Mayberry JC, Moneta GL, Taylor LM Jr, Porter JM. Fifteen-year results of ambulatory compression therapy for chronic venous ulcers. Surgery 1991; 109:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9079/abstract/3\">",
"      Barr DM. The Unna's boot as a treatment for venous ulcers. Nurse Pract 1996; 21:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9079/abstract/4\">",
"      Keller A, M&uuml;ller ML, Calow T, et al. Bandage pressure measurement and training: simple interventions to improve efficacy in compression bandaging. Int Wound J 2009; 6:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9079/abstract/5\">",
"      Moffatt C. Variability of pressure provided by sustained compression. Int Wound J 2008; 5:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9079/abstract/6\">",
"      Mosti G, Partsch H. Inelastic bandages maintain their hemodynamic effectiveness over time despite significant pressure loss. J Vasc Surg 2010; 52:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9079/abstract/7\">",
"      de Araujo T, Valencia I, Federman DG, Kirsner RS. Managing the patient with venous ulcers. Ann Intern Med 2003; 138:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9079/abstract/8\">",
"      Polignano R, Bonadeo P, Gasbarro S, Allegra C. A randomised controlled study of four-layer compression versus Unna's Boot for venous ulcers. J Wound Care 2004; 13:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9079/abstract/9\">",
"      Hendricks WM, Swallow RT. Management of stasis leg ulcers with Unna's boots versus elastic support stockings. J Am Acad Dermatol 1985; 12:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9079/abstract/10\">",
"      O'Meara S, Cullum NA, Nelson EA. Compression for venous leg ulcers. Cochrane Database Syst Rev 2009; :CD000265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9079/abstract/11\">",
"      O'Meara S, Tierney J, Cullum N, et al. Four layer bandage compared with short stretch bandage for venous leg ulcers: systematic review and meta-analysis of randomised controlled trials with data from individual patients. BMJ 2009; 338:b1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9079/abstract/12\">",
"      Thomas S, Fram P. Laboratory-based evaluation of a compression-bandaging system. Nurs Times 2003; 99:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9079/abstract/13\">",
"      J&uuml;nger M, Ladwig A, Bohbot S, Haase H. Comparison of interface pressures of three compression bandaging systems used on healthy volunteers. J Wound Care 2009; 18:474, 476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9079/abstract/14\">",
"      Dale JJ, Ruckley CV, Gibson B, et al. Multi-layer compression: comparison of four different four-layer bandage systems applied to the leg. Eur J Vasc Endovasc Surg 2004; 27:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9079/abstract/15\">",
"      Blair SD, Wright DD, Backhouse CM, et al. Sustained compression and healing of chronic venous ulcers. BMJ 1988; 297:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9079/abstract/16\">",
"      Nelson EA, Iglesias CP, Cullum N, et al. Randomized clinical trial of four-layer and short-stretch compression bandages for venous leg ulcers (VenUS I). Br J Surg 2004; 91:1292.",
"     </a>",
"    </li>",
"    <li>",
"     Tips for the application of a compression bandage. file://en.hartmann.info/application_bandage.php (Accessed on September 28, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9079/abstract/18\">",
"      Moffatt C. Four-layer bandaging: from concept to practice. Int J Low Extrem Wounds 2002; 1:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9079/abstract/19\">",
"      Heede G. [The P&uuml;tter bandage]. Z Arztl Fortbild (Jena) 1981; 75:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9079/abstract/20\">",
"      Partsch H. Compression therapy. Int Angiol 2010; 29:391.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15199 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_55_9079=[""].join("\n");
var outline_f8_55_9079=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H442681185\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H442681058\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H442681066\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H622447523\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H442681073\">",
"      BANDAGE TYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H442681080\">",
"      Rigid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H622445792\">",
"      Elastic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H622447204\">",
"      CHOICE OF COMPRESSION BANDAGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H442681115\">",
"      APPLICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H622448135\">",
"      General tips for compression bandage placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H442681122\">",
"      Unna boot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H442681129\">",
"      Multilayer compression bandages",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H622445806\">",
"      - Padding (layer 1)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H622445813\">",
"      - Crepe bandage (layer 2)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H622445820\">",
"      - Extensible elastic bandage (layer 3)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H622445827\">",
"      - Cohesive elastic bandage (layer 4)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H622447437\">",
"      PATIENT INSTRUCTIONS AND FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H442681136\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H442681185\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15199\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15199|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/56/22403\" title=\"figure 1\">",
"      Nerves prone to stretch or compression in lithotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/58/7074\" title=\"figure 2\">",
"      Compression bandage placement",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/40/19078?source=related_link\">",
"      Clinical assessment of wounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=related_link\">",
"      Medical management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=related_link\">",
"      Overview and management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/47/41714?source=related_link\">",
"      Patient information: Varicose veins and other vein disease in the legs (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_55_9080="Scarlet fever rash";
var content_f8_55_9080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scarlet fever rash",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 462px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fine papules, \"sandpaper-like\" rash on trunk of child with scarlet fever.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: George A. Datto, III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_55_9080=[""].join("\n");
var outline_f8_55_9080=null;
var title_f8_55_9081="Perioral (periorificial) dermatitis";
var content_f8_55_9081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Perioral (periorificial) dermatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/55/9081/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/55/9081/contributors\">",
"     Jason Reichenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/55/9081/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/55/9081/contributors\">",
"     Mark V Dahl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/55/9081/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/55/9081/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/55/9081/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5544598\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioral dermatitis (POD), also known as periorificial dermatitis, is a skin disorder that typically presents with multiple small inflammatory papules around the mouth, nose, or eyes. Although the name &ldquo;perioral dermatitis&rdquo; suggests a primarily eczematous condition, POD most often resembles an acneiform or rosacea-like eruption with or without associated features of a mild eczematous dermatitis. The pathogenesis of POD is poorly understood; both intrinsic and extrinsic factors may contribute to this disorder. &nbsp;",
"   </p>",
"   <p>",
"    Although POD may resolve over time after the discontinuation of topical corticosteroids and the elimination of skin irritants, the cosmetic appearance of lesions prompts many patients to seek treatment. Topical antiinflammatory agents and topical or systemic antibiotics constitute the major pharmacologic options for therapy.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and management of POD will be discussed here. The differential diagnosis of disorders that present with inflammation of facial skin is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/552?source=see_link\">",
"     \"Approach to the patient with facial erythema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2875928\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;POD was first described in 1957 under the moniker &ldquo;light sensitive seborrheid&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/1\">",
"     1",
"    </a>",
"    ]. Since then, an association with light exposure has largely been discounted [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In 1964, &ldquo;perioral dermatitis&rdquo; was introduced as the preferred term to refer to this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/4\">",
"     4",
"    </a>",
"    ]. More recently, some authors have advocated for utilization of the term &ldquo;periorificial dermatitis,&rdquo; a name that reflects the various potential sites of POD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5544626\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5544605\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;POD occurs worldwide and in individuals of all racial and ethnic backgrounds. Although women between the ages of 16 and 45 constitute the vast majority of patients affected by POD, POD may also occur in older individuals, men, and children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Childhood POD most frequently occurs under the age of five years, and may develop in infants as young as six months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/5\">",
"     5",
"    </a>",
"    ]. Girls may be slightly more likely to develop POD than boys. In a retrospective study, 46 of 79 children and adolescents with POD (58 percent) were female [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5544612\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathways that lead to the development of POD are not well understood. Deficiencies in skin barrier function and features of atopy have been detected at increased frequency in patients with POD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Although it is conceivable that these factors could augment the risk for persistent cutaneous inflammation after to exposures to external irritants [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/9-11\">",
"     9-11",
"    </a>",
"    ], a definitive role for skin barrier dysfunction and atopic diatheses in POD has not been established.",
"   </p>",
"   <p>",
"    Topical corticosteroid use is frequently reported in association with POD, with the classic history being a papular and slightly scaly facial eruption that initially improves with topical corticosteroid use, but recurs or worsens with continued use or attempts to discontinue corticosteroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/2,5,12,13\">",
"     2,5,12,13",
"    </a>",
"    ]. Whether topical corticosteroids are capable of inducing POD during treatment of unrelated facial dermatoses or whether they may simply exacerbate preexisting POD remains uncertain. Reports vary widely on the proportion of patients who recount a history of topical corticosteroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/2,5,10,14,15\">",
"     2,5,10,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the uncertainty in the specific role of corticosteroids in POD, there appears to be a connection between POD and topical corticosteroid use, particularly with potent formulations. There is an impression that fluorinated topical corticosteroids are particularly likely to contribute to POD, which may be related to their high potencies, rather than a specific effect of fluorination [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/2,16,17\">",
"     2,16,17",
"    </a>",
"    ]. Further support for a contributory role of corticosteroids arises from reports of POD that developed after the administration of oral [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/18,19\">",
"     18,19",
"    </a>",
"    ] or inhaled corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reason for an association between POD and corticosteroids remains unclear. Some authors have suggested that corticosteroid-induced damage to the epidermal barrier may be a contributing factor [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to topical corticosteroids, several other factors have been proposed as potential contributors to POD, including fluorinated toothpaste, skin moisturizers and cosmetic products, fusobacteria,",
"    <em>",
"     Candida albicans",
"    </em>",
"    , hormonal fluctuations in women, and oral contraceptive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/2,3,12,22-27\">",
"     2,3,12,22-27",
"    </a>",
"    ]. Whether these factors truly contribute to the development of POD is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/2,14\">",
"     2,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5544626\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;POD typically manifests as multiple 1 to 2 mm clustered erythematous papules, papulovesicles, or papulopustules with or without mild scale (",
"    <a class=\"graphic graphic_picture graphicRef60390 graphicRef64577 graphicRef73223 graphicRef63864 graphicRef62705 graphicRef50527 graphicRef65367 graphicRef73779 \" href=\"UTD.htm?43/46/44778\">",
"     picture 1A-H",
"    </a>",
"    ). In some patients, features consistent with a mild eczematous dermatitis also are present. Occasionally, the eczematous component is prominent.",
"   </p>",
"   <p>",
"    The inflammatory papules and scaling of POD occur most frequently in the perioral region, but a narrow zone around the vermilion border of the lip is usually spared [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/3\">",
"     3",
"    </a>",
"    ]. Less often, the perinasal and periorbital areas are sites of significant involvement (",
"    <a class=\"graphic graphic_picture graphicRef51230 graphicRef70512 \" href=\"UTD.htm?19/26/19881\">",
"     picture 2A-B",
"    </a>",
"    ). In a retrospective study of 79 children and adolescents with POD, perioral, perinasal, or periocular lesions were present in 70, 43, and 25 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/5\">",
"     5",
"    </a>",
"    ]. Lesions in these classic locations may also be accompanied by lesions in other areas, such as the cheeks, chin, forehead, and neck [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    POD may be asymptomatic or may be accompanied by mild to moderate stinging or burning sensations in the affected areas [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/7\">",
"     7",
"    </a>",
"    ]. The skin lesions usually resolve without scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17210921\">",
"    <span class=\"h2\">",
"     Granulomatous periorificial dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatous periorificial dermatitis represents a clinical variant of POD that typically occurs in prepubescent children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. The term Afro-Caribbean childhood eruption has also been used to describe this condition in black children. Children typically develop numerous small, flesh-colored, red-brown, or yellow-brown inflammatory papules in perioral, perinasal, or periocular areas (",
"    <a class=\"graphic graphic_picture graphicRef50340 \" href=\"UTD.htm?14/21/14675\">",
"     picture 3",
"    </a>",
"    ). Papulopustules and papulovesicles are typically absent, and occasionally, sites other than the face are affected [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599784\">",
"    <span class=\"h2\">",
"     Disease course",
"    </span>",
"    &nbsp;&mdash;&nbsp;POD is generally considered a benign and self-limited disorder. In some patients, POD resolves within a few months without pharmacologic therapy, while in others, the disorder may persist for several years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical corticosteroid use may contribute to the chronicity of POD. Although improvement may be noted early in the course of corticosteroid treatment, continued use may perpetuate or exacerbate the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1586608\">",
"     'Approach to therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5544633\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of POD can usually be made via assessment of the patient history and recognition of the classic clinical features. The presence of multiple small inflammatory papules, papulovesicles, or papulopustules clustered on the perioral, perinasal, or periocular skin suggests this diagnosis. The following additional findings also support a diagnosis of POD:",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sparing of the skin immediately adjacent to the vermilion border of the lip",
"     </li>",
"     <li>",
"      Coexisting features of eczematous dermatitis",
"     </li>",
"     <li>",
"      Burning or stinging sensations",
"     </li>",
"     <li>",
"      Recent use of topical, nasal, or inhaled corticosteroids",
"     </li>",
"     <li>",
"      History of disease flares after topical corticosteroid withdrawal",
"     </li>",
"     <li>",
"      Absence of comedones (comedones are a manifestation of acne vulgaris)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Skin biopsies rarely are necessary, but can be used to differentiate POD from other disorders when the diagnosis is uncertain. The histopathologic findings of POD are nonspecific and vary with the type of lesion biopsied: scaling, eczematous-appearing areas show parakeratosis, epidermal spongiosis, and mild acanthosis, and biopsies of papules typically exhibit perifollicular and perivascular lymphocytic infiltrates. Biopsies taken from lesions of granulomatous periorificial dermatitis demonstrate epithelioid granulomas that resemble those found in granulomatous rosacea [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/552?source=see_link&amp;anchor=H402950#H402950\">",
"     \"Approach to the patient with facial erythema\", section on 'Biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link&amp;anchor=H433591#H433591\">",
"     \"Rosacea: Pathogenesis, clinical features, and diagnosis\", section on 'Granulomatous rosacea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serological studies are not useful for confirming a diagnosis of POD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5544661\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple other skin disorders may present with inflammatory eruptions around the mouth, nose, or eyes. Examples include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Acne vulgaris &ndash;",
"      </strong>",
"      Acne vulgaris is a common disorder that manifests as comedones and inflammatory papules or pustules (",
"      <a class=\"graphic graphic_picture graphicRef70809 graphicRef80536 \" href=\"UTD.htm?14/7/14456\">",
"       picture 4A-B",
"      </a>",
"      ). Although the detection of comedones on the skin supports a diagnosis of acne vulgaris, acne vulgaris and POD may coexist. Unlike acne vulgaris, scarring is uncommon in POD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6474?source=see_link&amp;anchor=H10#H10\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris\", section on 'Clinical manifestations and classification'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Rosacea &ndash;",
"      </strong>",
"      Papulopustular rosacea presents with inflammatory papules and pustules that are primarily distributed on the central face (",
"      <a class=\"graphic graphic_picture graphicRef67890 \" href=\"UTD.htm?40/52/41794\">",
"       picture 5",
"      </a>",
"      ). Centrofacial erythema and telangiectasias may also be present. A predilection for the cheeks rather than periorificial sites suggests a diagnosis of papulopustular rosacea. In the absence of other findings consistent with rosacea, lesions of granulomatous rosacea may be impossible to distinguish from granulomatous periorificial dermatitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link\">",
"       \"Rosacea: Pathogenesis, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Seborrheic dermatitis &ndash;",
"      </strong>",
"      Seborrheic dermatitis is a common inflammatory condition that frequently presents with erythema and scale involving the perinasal skin (",
"      <a class=\"graphic graphic_picture graphicRef59104 \" href=\"UTD.htm?27/42/28320\">",
"       picture 6",
"      </a>",
"      ). Scaling macules and patches are typically present. In contrast to POD, small papules are not a typical feature of seborrheic dermatitis and a perioral distribution is unusual in seborrheic dermatitis. The detection of seborrheic dermatitis in other commonly affected sites, such as the scalp, eyebrows, nasolabial folds, and chest, can be useful for diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/28/21961?source=see_link\">",
"       \"Seborrheic dermatitis in adolescents and adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Allergic contact dermatitis &ndash;",
"      </strong>",
"      Allergic contact dermatitis is a manifestation of a type IV hypersensitivity reaction to agents that come in contact with the skin. Patients may present with inflammatory papules, vesicles, weeping, or crusting (",
"      <a class=\"graphic graphic_picture graphicRef67215 \" href=\"UTD.htm?0/43/694\">",
"       picture 7",
"      </a>",
"      ). The distribution of lesions is dependent upon the specific sites of contact with the inciting agent. Unlike POD, intense pruritus is usually present, scale is often prominent, and lesions fail to improve with antibiotic therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11943?source=see_link\">",
"       \"Clinical features and diagnosis of allergic contact dermatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Irritant contact dermatitis &ndash;",
"      </strong>",
"      The clinical findings of irritant contact dermatitis vary based upon the nature of the external insult and site of involvement. Papules, vesicles, scale, erythema, or edema may be seen. Unlike allergic contact dermatitis, but similar to POD, a burning sensation, rather than pruritus, is often the predominating symptom. The patient history is of value for identifying this diagnosis. As an example, irritant dermatitis related to chronic lip-licking behavior can resemble POD (",
"      <a class=\"graphic graphic_picture graphicRef54887 \" href=\"UTD.htm?16/61/17366\">",
"       picture 8",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link&amp;anchor=H18#H18\">",
"       \"Overview of dermatitis\", section on 'Irritant contact dermatitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Impetigo &ndash;",
"      </strong>",
"      Impetigo is a common staphylococcal or streptococcal skin infection that most frequently occurs in children. The perinasal skin is a common site for involvement. Erosions, vesicles, and yellow crusts may be present (",
"      <a class=\"graphic graphic_picture graphicRef82281 \" href=\"UTD.htm?18/22/18787\">",
"       picture 9",
"      </a>",
"      ). Scaling and acne-like papules are uncommon. Gram stains and bacterial cultures can be used to confirm this diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=see_link\">",
"       \"Impetigo\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Dermatophyte infections",
"      </strong>",
"      &ndash; Tinea corporis and tinea barbae may present with inflammatory papules or pustules on the face (",
"      <a class=\"graphic graphic_picture graphicRef78234 \" href=\"UTD.htm?42/55/43892\">",
"       picture 10",
"      </a>",
"      ). Unlike POD, dermatophyte infections almost always have an asymmetrical distribution. A potassium hydroxide preparation (KOH) is useful for diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link\">",
"       \"Dermatophyte (tinea) infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H4044416#H4044416\">",
"       \"Dermatologic procedures\", section on 'Potassium hydroxide (KOH) prep'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less common causes of facial lesions that may exhibit features suggestive of POD include",
"    <em>",
"     Demodex",
"    </em>",
"    folliculitis, which can demonstrate numerous",
"    <em>",
"     Demodex",
"    </em>",
"    mites on KOH preparation, lupus miliaris disseminatus faciei (which may represent a variant of rosacea) (",
"    <a class=\"graphic graphic_picture graphicRef56241 \" href=\"UTD.htm?39/41/40597\">",
"     picture 11",
"    </a>",
"    ), Gram-negative folliculitis, and eosinophilic folliculitis with or without associated human immunodeficiency virus infection (",
"    <a class=\"graphic graphic_picture graphicRef54404 \" href=\"UTD.htm?33/2/33839\">",
"     picture 12",
"    </a>",
"    ). In addition, acrodermatitis enteropathica, a rare disorder associated with zinc deficiency that typically first manifests in early childhood, often presents with periorificial and acral erythematous, scaling patches and plaques (",
"    <a class=\"graphic graphic_picture graphicRef71329 \" href=\"UTD.htm?39/34/40481\">",
"     picture 13",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/38\">",
"     38",
"    </a>",
"    ]. Necrolytic migratory erythema, a feature associated with glucagon-secreting pancreatic islet cell tumors, may also present with inflammatory periorificial lesions (",
"    <a class=\"graphic graphic_picture graphicRef76162 \" href=\"UTD.htm?15/3/15415\">",
"     picture 14",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24359?source=see_link\">",
"     \"HIV-associated eosinophilic folliculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=see_link&amp;anchor=H8#H8\">",
"     \"Zinc deficiency and supplementation in children and adolescents\", section on 'Acrodermatitis enteropathica'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link&amp;anchor=H4#H4\">",
"     \"Cutaneous manifestations of internal malignancy\", section on 'Necrolytic migratory erythema'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3579734\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;POD may resolve within a few months without pharmacologic therapy if topical corticosteroid use is discontinued and other potentially exacerbating factors are eliminated. However, since the appearance of the skin lesions is frequently distressing for patients and the disease course is variable, patients often desire intervention to reduce the duration of symptoms. (See",
"    <a class=\"local\" href=\"#H599784\">",
"     'Disease course'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Data on the topical and systemic treatment options for POD are limited. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    , topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    , topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    , and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    are the agents with the greatest evidence for efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1586608\">",
"    <span class=\"h2\">",
"     Approach to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our general approach to adults and children with POD involves the discontinuation of topical corticosteroids and the avoidance of skin care products and cosmetics that may irritate or occlude the skin. This approach, which is also referred to as &ldquo;zero therapy,&rdquo; is supported by the observation that many vehicle or placebo-treated patients in randomized trials have improved within two to three months without active therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/11,39,40\">",
"     11,39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the cessation of topical corticosteroids is well-accepted as an important component of management, patients typically become distressed when disease flares occur following the cessation of corticosteroid therapy. Some clinicians attempt to reduce the likelihood of a rebound flare by either transitioning patients utilizing high or medium potency topical corticosteroids to low potency agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    1% or slowly tapering the frequency of corticosteroid application prior to treatment cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/3,6,8,15\">",
"     3,6,8,15",
"    </a>",
"    ]. The benefit of these techniques is unproven.",
"   </p>",
"   <p>",
"    An effort to eliminate potential skin irritants typically involves cleansing the skin with water alone and limiting the use of topical products on the face to the occasional &ldquo;only as needed&rdquo; application of a bland, nonocclusive moisturizing lotion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/8,23\">",
"     8,23",
"    </a>",
"    ]. However, such extensive avoidance of cosmetic and skin care products is not feasible for all patients.",
"   </p>",
"   <p>",
"    In an attempt to accelerate clinical improvement, we usually also prescribe pharmacological therapy. For children and adults with mild to moderate eruptions (the presence of several or more lesions that do not cause the patient significant emotional distress), we typically initiate therapy with a topical agent due to the relatively low risk for drug-induced systemic adverse effects. We favor topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    , as this agent has the most evidence in support of its efficacy. However, the expense of this drug is sometimes a limiting factor. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    are less expensive options for therapy.",
"   </p>",
"   <p>",
"    For patients who present with moderate to severe POD (numerous papules, large areas of confluent involvement, bothersome symptoms, or significantly emotionally distressing POD) or milder disease that is refractory to topical therapy, we favor the use of oral tetracyclines as initial therapy. In children under the age of nine, tetracyclines are contraindicated; oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    is the preferred systemic agent for these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H850368\">",
"    <span class=\"h2\">",
"     First-line topical pharmacological agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the topical agents prescribed for POD,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    1% cream has the most data in support of its efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/11,39,41,42\">",
"     11,39,41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H850471\">",
"    <span class=\"h3\">",
"     Topical calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     Pimecrolimus",
"    </a>",
"    1% cream is a topical calcineurin inhibitor. In a multicenter randomized trial in which 124 adults were treated for up to four weeks with twice daily applications of pimecrolimus 1% cream or a vehicle cream, pimecrolimus therapy was associated with more rapid improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/11\">",
"     11",
"    </a>",
"    ]. After eight days, greater than 50 percent reductions in disease severity scores occurred in 24 of 60 patients in the pimecrolimus group (40 percent) and only 7 of 64 patients in the vehicle group (11 percent). In addition, the median time to response was 14 versus 28 days. Patients with a history of topical corticosteroid use appeared to respond best to pimecrolimus. However, the benefit of pimecrolimus dissipated over time; by day 29, disease severity scores were similar in both groups.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    for POD was also supported by a smaller randomized trial in which 40 adults were treated with either pimecrolimus 1% cream or vehicle cream applied twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/39\">",
"     39",
"    </a>",
"    ]. Throughout the four weeks of treatment, the reduction in disease severity was greater in patients treated with pimecrolimus, and after the first week of treatment, at least a 50 percent reduction in the disease severity score was present in 50 versus 15 percent of patients. As in the larger trial, the duration of treatment benefit was limited. Four weeks after the end of treatment, the response rates were similar in both groups. No randomized trials of pimecrolimus therapy have been performed in children.",
"   </p>",
"   <p>",
"    The efficacy of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , an ointment-based calcineurin inhibitor, has not been formally studied, but improvement after tacrolimus ointment has been reported in a few patients with granulomatous periorificial dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/7,31,43\">",
"     7,31,43",
"    </a>",
"    ]. Of note, the development of rosacea-like eruptions has also been associated with treatment with this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We instruct patients to apply",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    twice daily. If signs of improvement are not evident after one month, we consider the initiation of oral antibiotic therapy. &nbsp;",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    is usually well-tolerated. In the randomized trials, adverse effects were mild and primarily limited to the sites of treatment and post-treatment disease flares did not appear to occur after the cessation of pimecrolimus therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/11,39\">",
"     11,39",
"    </a>",
"    ]. The US Food and Drug Administration has placed a boxed warning on topical calcineurin inhibitors due to concerns about an association between these agents and malignancies; however, the risk for such events appears to be minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17211545\">",
"    <span class=\"h3\">",
"     Topical erythromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    for POD is supported by an 80-day randomized trial and documentation of clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/40,46\">",
"     40,46",
"    </a>",
"    ]. In the randomized trial, 99 patients who were treated with either a topical erythromycin emulsion containing 1% erythromycin base (treatment regimen unspecified), oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    (500 mg twice daily for 10 days and 250 mg twice daily for 10 days), or a placebo pill returned for the assessment of the response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/40\">",
"     40",
"    </a>",
"    ]. Both drugs were superior to placebo and statistically significant differences between the response to topical erythromycin and oral tetracycline were not detected. (See",
"    <a class=\"local\" href=\"#H1586965\">",
"     'Oral tetracyclines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When treating mild to moderate POD with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    , we typically prescribe twice daily application of erythromycin 2% gel. The duration of treatment is usually four to eight weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17211552\">",
"    <span class=\"h3\">",
"     Topical metronidazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no vehicle-controlled randomized trials have evaluated the efficacy of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    in POD, metronidazole 1% cream was compared to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    (250 mg twice daily) in an eight-week randomized trial of 108 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients in both groups improved, but the response of papular lesions was slower with metronidazole therapy. (See",
"    <a class=\"local\" href=\"#H1586965\">",
"     'Oral tetracyclines'",
"    </a>",
"    below.) Additional data on topical metronidazole comes from small case series and case reports that document efficacy in children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/14,47\">",
"     14,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We typically treat mild to moderate POD with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    lotion, gel, or cream (0.75% or 1%) once daily, and continue treatment for at least eight weeks. Improvement is often noted within this period, but longer periods of treatment may be required in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/5,15\">",
"     5,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1587100\">",
"    <span class=\"h2\">",
"     First-line systemic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common agents used for systemic treatment of POD are oral tetracyclines. Children under the age of nine should not be treated with tetracyclines due to the potential for adverse effects on teeth and bone. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    is an alternative therapy for young children and other patients who cannot tolerate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    therapy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1586965\">",
"    <span class=\"h3\">",
"     Oral tetracyclines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although oral tetracyclines are well-accepted as effective treatments for perioral dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/2,25,48-50\">",
"     2,25,48-50",
"    </a>",
"    ], the mechanism through which these agents improve POD is unknown. The antiinflammatory effects of these agents may account for their efficacy.",
"   </p>",
"   <p>",
"    Two randomized trials have supported the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    in POD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       Tetracycline",
"      </a>",
"      (500 mg twice daily for 10 days followed by 250 mg twice daily for 10 days) was compared to a topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      emulsion (treatment regimen unspecified) and a placebo pill in an 80-day unblinded randomized trial in which 99 out of 120 patients returned for follow-up evaluation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/40\">",
"       40",
"      </a>",
"      ]. Papule counts were significantly lower in the tetracycline group than in the placebo group between days 20 to 40, suggesting tetracycline therapy increased the rate of improvement. At day 40, more than 80 percent of patients in the placebo group had more than 10 papules remaining, compared with none of the patients treated with tetracycline. The trial did not find significant differences in the efficacy of oral tetracycline and topical erythromycin. (See",
"      <a class=\"local\" href=\"#H17211545\">",
"       'Topical erythromycin'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      An eight-week multicenter randomized trial of 108 adult patients with moderate POD compared oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      (250 mg twice daily) to twice daily applications of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      1% cream [",
"      <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/34\">",
"       34",
"      </a>",
"      ]. Although both agents were associated with reduced lesion counts, patients treated with tetracycline improved more quickly. Significantly greater reductions in lesion counts were present in patients treated with tetracycline at four weeks (96 versus 67 percent) and eight weeks (100 versus 92 percent). Improvement in skin erythema was similar in the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A third randomized trial failed to find a difference in efficacy between oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    and no therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/51\">",
"     51",
"    </a>",
"    ]. However, the quality of this trial was poor, and the results were inconsistent with the findings of other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    are used for the treatment of POD. Doxycycline and minocycline are more expensive than tetracycline, but have the advantage of fewer restrictions on the timing of administration. No randomized trials have evaluated the efficacy of these agents, and their wide use is primarily based upon the evidence from the studies of tetracycline and a few case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/18,43\">",
"     18,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A typical course of oral tetracyclines for POD is approximately eight weeks. Typical doses for adolescent and adult patients with POD are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       Tetracycline",
"      </a>",
"      (250 to 500 mg twice daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      (50 to 100 mg twice daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       Minocycline",
"      </a>",
"      (50 to 100 mg twice daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment with tetracyclines is generally well tolerated. Gastrointestinal distress is a common adverse effect. Other potential side effects include photosensitivity and skin dyspigmentation. Treatment with tetracyclines is contraindicated in children under the age of nine due to the risk for permanent tooth discoloration and delayed bone growth [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1587085\">",
"    <span class=\"h3\">",
"     Oral erythromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    has not been evaluated in randomized trials, but based upon case reports and case series, the drug may be effective for young children and other patients who cannot tolerate tetracyclines [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/5,32,53-56\">",
"     5,32,53-56",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1586698\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional local therapies reported to be of benefit in small uncontrolled or case report studies include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    20% cream [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/57,58\">",
"     57,58",
"    </a>",
"    ], topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    1% lotion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/53,59\">",
"     53,59",
"    </a>",
"    ], topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/60\">",
"     60",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/60/17348?source=see_link\">",
"     adapalene",
"    </a>",
"    0.1% gel [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/61\">",
"     61",
"    </a>",
"    ], and topical sulfacetamide-sulfur combined with oral tetracycline [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/62\">",
"     62",
"    </a>",
"    ]. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    was reported to be effective in a young woman with features consistent with refractory granulomatous periorificial dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/63\">",
"     63",
"    </a>",
"    ]. In addition, we have anecdotally noted good responses to topical precipitated sulfur in patients with contraindications to standard treatments.",
"   </p>",
"   <p>",
"    Photodynamic therapy may be another option for the treatment of POD. This intervention was more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    gel in a split-face study of 21 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9081/abstract/59\">",
"     59",
"    </a>",
"    ]. However, seven patients dropped out of the study due to skin irritation related to photodynamic therapy and three patients developed treatment-related postinflammatory hyperpigmentation.",
"   </p>",
"   <p>",
"    Further study is necessary to determine the efficacy of all of these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22714874\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perioral dermatitis (also known as periorificial dermatitis) is an inflammatory condition of facial skin that primarily affects young women. Less frequently, the disorder occurs in older individuals, men, and children. (See",
"      <a class=\"local\" href=\"#H5544605\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although a variety of intrinsic and extrinsic factors have been proposed as contributors to POD, the pathogenesis of this disorder is not well-understood. The factor most frequently reported in association with the occurrence or persistence of POD is topical corticosteroid use. (See",
"      <a class=\"local\" href=\"#H5544612\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with POD typically present with small, inflammatory papules, papulovesicles, or papulopustules and scaling surrounding the mouth, nose, or eyes (",
"      <a class=\"graphic graphic_picture graphicRef60390 graphicRef64577 graphicRef73223 graphicRef63864 graphicRef62705 graphicRef50527 graphicRef65367 graphicRef73779 graphicRef51230 graphicRef70512 \" href=\"UTD.htm?0/6/101\">",
"       picture 1A-H, 2A-B",
"      </a>",
"      ). In patients with perioral lesions, the skin adjacent to the lip border is typically spared. (See",
"      <a class=\"local\" href=\"#H5544626\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic granulomatous periorificial dermatitis is a variant of POD that is typically seen in prepubertal children (",
"      <a class=\"graphic graphic_picture graphicRef50340 \" href=\"UTD.htm?14/21/14675\">",
"       picture 3",
"      </a>",
"      ). Histopathologic examination of lesional skin reveals a granulomatous infiltrate in these patients. (See",
"      <a class=\"local\" href=\"#H5544626\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical history and physical examination is usually sufficient for the diagnosis of POD. The histopathologic findings of POD are nonspecific, and skin biopsies are rarely necessary. (See",
"      <a class=\"local\" href=\"#H5544633\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of perioral dermatitis involves the discontinuation of topical corticosteroids and the avoidance of skin irritants. Although patients may eventually improve without additional interventions, pharmacologic therapy is often instituted in an attempt to accelerate lesion resolution. (See",
"      <a class=\"local\" href=\"#H1586608\">",
"       'Approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adults and children with mild to moderate perioral dermatitis who desire an attempt to accelerate improvement, we suggest treatment with topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"       pimecrolimus",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      and topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      are additional, less expensive options for therapy. (See",
"      <a class=\"local\" href=\"#H850368\">",
"       'First-line topical pharmacological agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adolescents and adults with moderate to severe perioral dermatitis or with milder disease refractory to topical agents who desire an attempt to accelerate improvement, we suggest treatment with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      may also be used for treatment. The response to oral antibiotic therapy is often slow; a typical course of treatment is two months. (See",
"      <a class=\"local\" href=\"#H1587100\">",
"       'First-line systemic agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children under the age of nine with moderate to severe perioral dermatitis or who fail treatment with topical agents, we suggest treatment with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Young children should not receive oral tetracyclines due to the potential for adverse effects on tooth and bone development. (See",
"      <a class=\"local\" href=\"#H1587100\">",
"       'First-line systemic agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/1\">",
"      Frumess GM, Lewis HM. Light sensitive seborrhoeide. Arch Dermato 1957; 75:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/2\">",
"      Wilkinson DS, Kirton V, Wilkinson JD. Perioral dermatitis: a 12-year review. Br J Dermatol 1979; 101:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/3\">",
"      Hafeez ZH. Perioral dermatitis: an update. Int J Dermatol 2003; 42:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/4\">",
"      MIHAN R, AYRES S Jr. PERIORAL DERMATITIS. Arch Dermatol 1964; 89:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/5\">",
"      Nguyen V, Eichenfield LF. Periorificial dermatitis in children and adolescents. J Am Acad Dermatol 2006; 55:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/6\">",
"      Kihiczak GG, Cruz MA, Schwartz RA. Periorificial dermatitis in children: an update and description of a child with striking features. Int J Dermatol 2009; 48:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/7\">",
"      Wollenberg A, Bieber T, Dirschka T, et al. Perioral dermatitis. J Dtsch Dermatol Ges 2011; 9:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/8\">",
"      Lipozencic J, Ljubojevic S. Perioral dermatitis. Clin Dermatol 2011; 29:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/9\">",
"      Dirschka T, Tronnier H, F&ouml;lster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol 2004; 150:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/10\">",
"      Dirschka T, Szliska C, Jackowski J, Tronnier H. Impaired skin barrier and atopic diathesis in perioral dermatitis. J Dtsch Dermatol Ges 2003; 1:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/11\">",
"      Schwarz T, Kreiselmaier I, Bieber T, et al. A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. J Am Acad Dermatol 2008; 59:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/12\">",
"      Hall CS, Reichenberg J. Evidence based review of perioral dermatitis therapy. G Ital Dermatol Venereol 2010; 145:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/13\">",
"      Cotterill JA. Perioral dermatitis. Br J Dermatol 1979; 101:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/14\">",
"      Boeck K, Abeck D, Werfel S, Ring J. Perioral dermatitis in children--clinical presentation, pathogenesis-related factors and response to topical metronidazole. Dermatology 1997; 195:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/15\">",
"      Laude TA, Salvemini JN. Perioral dermatitis in children. Semin Cutan Med Surg 1999; 18:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/16\">",
"      Sneddon I. Perioral dermatitis. Br J Dermatol 1972; 87:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/17\">",
"      Cohen HJ. Perioral dermatitis. J Am Acad Dermatol 1981; 4:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/18\">",
"      Adams SJ, Davison AM, Cunliffe WJ, Giles GR. Perioral dermatitis in renal transplant recipients maintained on corticosteroids and immunosuppressive therapy. Br J Dermatol 1982; 106:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/19\">",
"      Clementson B, Smidt AC. Periorificial dermatitis due to systemic corticosteroids in children: report of two cases. Pediatr Dermatol 2012; 29:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/20\">",
"      Held E, Ottevanger V, Petersen CS, Weismann K. [Perioral dermatitis in children under steroid inhalation therapy]. Ugeskr Laeger 1997; 159:7002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/21\">",
"      Peralta L, Morais P. Perioral dermatitis -- the role of nasal steroids. Cutan Ocul Toxicol 2012; 31:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/22\">",
"      Kalkoff KW, Buck A. [Etiology of perioral dermatitis]. Hautarzt 1977; 28:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/23\">",
"      Fritsch P, Pichler E, Linser I. [Perioral dermatitis]. Hautarzt 1989; 40:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/24\">",
"      Ehlers G. [Rosacea-like dermatitis of the face. \"Perioral dermatitis\"]. Hautarzt 1969; 20:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/25\">",
"      Cochran RE, Thomson J. Perioral dermatitis: a reappraisal. Clin Exp Dermatol 1979; 4:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/26\">",
"      Bradford LG, Montes LF. Perioral dermatitis and Candida albicans. Arch Dermatol 1972; 105:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/27\">",
"      Malik R, Quirk CJ. Topical applications and perioral dermatitis. Australas J Dermatol 2000; 41:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/28\">",
"      Kim YJ, Shin JW, Lee JS, et al. Childhood granulomatous periorificial dermatitis. Ann Dermatol 2011; 23:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/29\">",
"      Lucas CR, Korman NJ, Gilliam AC. Granulomatous periorificial dermatitis: a variant of granulomatous rosacea in children? J Cutan Med Surg 2009; 13:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/30\">",
"      Zalaudek I, Di Stefani A, Ferrara G, Argenziano G. Childhood granulomatous periorificial dermatitis: a controversial disease. J Dtsch Dermatol Ges 2005; 3:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/31\">",
"      Hussain W, Daly BM. Granulomatous periorificial dermatitis in an 11-year-old boy: dramatic response to tacrolimus. J Eur Acad Dermatol Venereol 2007; 21:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/32\">",
"      Urbatsch AJ, Frieden I, Williams ML, et al. Extrafacial and generalized granulomatous periorificial dermatitis. Arch Dermatol 2002; 138:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/33\">",
"      Gutte R, Holmukhe S, Garg G, et al. Childhood granulomatous periorificial dermatitis in children with extra-facial involvement. Indian J Dermatol Venereol Leprol 2011; 77:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/34\">",
"      Veien NK, Munkvad JM, Nielsen AO, et al. Topical metronidazole in the treatment of perioral dermatitis. J Am Acad Dermatol 1991; 24:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/35\">",
"      Frieden IJ, Prose NS, Fletcher V, Turner ML. Granulomatous perioral dermatitis in children. Arch Dermatol 1989; 125:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/36\">",
"      Hogan DJ. Perioral dermatitis. Curr Probl Dermatol 1995; 22:98.",
"     </a>",
"    </li>",
"    <li>",
"     Weedon D. The granulomatous reaction pattern. In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, 2010. p.169.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/38\">",
"      Kharfi M, El F&eacute;kih N, Aounallah-Skhiri H, et al. Acrodermatitis enteropathica: a review of 29 Tunisian cases. Int J Dermatol 2010; 49:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/39\">",
"      Oppel T, Pavicic T, Kamann S, et al. Pimecrolimus cream (1%) efficacy in perioral dermatitis - results of a randomized, double-blind, vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol 2007; 21:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/40\">",
"      Weber K, Thurmayr R, Meisinger A. A topical erythromycin preparation and oral tetracycline for the treatment of perioral dermatitis: a placebo controlled trial. J Dermatol Treat 1993; 4:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/41\">",
"      Rodr&iacute;guez-Mart&iacute;n M, S&aacute;ez-Rodr&iacute;guez M, Carnerero-Rodr&iacute;guez A, et al. Treatment of perioral dermatitis with topical pimecrolimus. J Am Acad Dermatol 2007; 56:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/42\">",
"      M&oslash;rtz CG, Deleuran MS. [A case of childhood granulomatous perioral dermatitis (CGPD) in a three year old boy from Madagascar]. Ugeskr Laeger 2008; 170:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/43\">",
"      Misago N, Nakafusa J, Narisawa Y. Childhood granulomatous periorificial dermatitis: lupus miliaris disseminatus faciei in children? J Eur Acad Dermatol Venereol 2005; 19:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/44\">",
"      Fujiwara S, Okubo Y, Irisawa R, Tsuboi R. Rosaceiform dermatitis associated with topical tacrolimus treatment. J Am Acad Dermatol 2010; 62:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/45\">",
"      Berger TG, Duvic M, Van Voorhees AS, et al. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006; 54:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/46\">",
"      Weber K. How I treat perioral dermatitis: non-compliance with the treatment guidelines. Dermatology 2003; 207:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/47\">",
"      Zip CM. Innovative use of topical metronidazole. Dermatol Clin 2010; 28:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/48\">",
"      Weber K, Thurmayr R. Critical appraisal of reports on the treatment of perioral dermatitis. Dermatology 2005; 210:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/49\">",
"      Macdonald A, Feiwel M. Perioral dermatitis: aetiology and treatment with tetracycline. Br J Dermatol 1972; 87:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/50\">",
"      Miller WS. Tetracycline in the treatment of perioral dermatitis. N C Med J 1971; 32:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/51\">",
"      Schubert E, Beetz HM, R&ouml;ckl H. [Value of tetracycline therapy in perioral dermatitis]. Hautarzt 1973; 24:253.",
"     </a>",
"    </li>",
"    <li>",
"     Comprehensive Dermatologic Drug Therapy, Wolverton SE (Ed), Saunders Elsevier, Philadelphia 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/53\">",
"      Coskey RJ. Perioral dermatitis. Cutis 1984; 34:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/54\">",
"      Choi YL, Lee KJ, Cho HJ, et al. Case of childhood granulomatous periorificial dermatitis in a Korean boy treated by oral erythromycin. J Dermatol 2006; 33:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/55\">",
"      Weston WL, Morelli JG. Identical twins with perioral dermatitis. Pediatr Dermatol 1998; 15:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/56\">",
"      Henningsen E, Bygum A. Budesonide-induced periorificial dermatitis presenting as chalazion and blepharitis. Pediatr Dermatol 2011; 28:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/57\">",
"      Jansen T. Azelaic acid as a new treatment for perioral dermatitis: results from an open study. Br J Dermatol 2004; 151:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/58\">",
"      Jansen T, Melnik BC, Schadendorf D. Steroid-induced periorificial dermatitis in children--clinical features and response to azelaic acid. Pediatr Dermatol 2010; 27:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/59\">",
"      Richey DF, Hopson B. Photodynamic therapy for perioral dermatitis. J Drugs Dermatol 2006; 5:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/60\">",
"      Wilson RG. Topical tetracycline in the treatment of perioral dermatitis. Arch Dermatol 1979; 115:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/61\">",
"      Jansen T. Perioral dermatitis successfully treated with topical adapalene. J Eur Acad Dermatol Venereol 2002; 16:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/62\">",
"      Bendl BJ. Perioral dermatitis: etiology and treatment. Cutis 1976; 17:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9081/abstract/63\">",
"      Smith KW. Perioral dermatitis with histopathologic features of granulomatous rosacea: successful treatment with isotretinoin. Cutis 1990; 46:413.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13622 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-2E861B2D37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_55_9081=[""].join("\n");
var outline_f8_55_9081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22714874\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5544598\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2875928\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5544605\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5544612\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5544626\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17210921\">",
"      Granulomatous periorificial dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H599784\">",
"      Disease course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5544633\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5544661\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3579734\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1586608\">",
"      Approach to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H850368\">",
"      First-line topical pharmacological agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H850471\">",
"      - Topical calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17211545\">",
"      - Topical erythromycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17211552\">",
"      - Topical metronidazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1587100\">",
"      First-line systemic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1586965\">",
"      - Oral tetracyclines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1587085\">",
"      - Oral erythromycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1586698\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22714874\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13622\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13622|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/12/26819\" title=\"picture 1A\">",
"      Perioral dermatitis papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/17/8469\" title=\"picture 1B\">",
"      Perioral dermatitis lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/51/22326\" title=\"picture 1C\">",
"      Perioral dermatitis in a male",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/29/44497\" title=\"picture 1D\">",
"      Perioral dermatitis in child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/20/1348\" title=\"picture 1E\">",
"      Perioral dermatitis papulopustular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/15/38132\" title=\"picture 1F\">",
"      Severe perioral dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/56/43910\" title=\"picture 1G\">",
"      Severe perioral dermatitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/39/22131\" title=\"picture 1H\">",
"      Perioral dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/7/23666\" title=\"picture 2A\">",
"      Periorificial dermatitis - perinasal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/24/29062\" title=\"picture 2B\">",
"      Periorificial dermatitis - periocular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/21/14675\" title=\"picture 3\">",
"      Granulomatous periorificial dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/26/36258\" title=\"picture 4A\">",
"      Inflammatory acne",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/4/28739\" title=\"picture 4B\">",
"      Acne open comedones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/52/41794\" title=\"picture 5\">",
"      Rosacea papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/42/28320\" title=\"picture 6\">",
"      Seborrheic dermatitis face 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/43/694\" title=\"picture 7\">",
"      Allergic contact dermatitis face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/61/17366\" title=\"picture 8\">",
"      Lip-licking dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/22/18787\" title=\"picture 9\">",
"      Impetigo crusted lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/55/43892\" title=\"picture 10\">",
"      Tinea faciei",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/41/40597\" title=\"picture 11\">",
"      Lupus miliaris disseminatus faciei",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/2/33839\" title=\"picture 12\">",
"      Eosinophilic folliculitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/34/40481\" title=\"picture 13\">",
"      Acrodermatitis enteropathica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/3/15415\" title=\"picture 14\">",
"      Necrolytic migratory erythema perioral",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/34/552?source=related_link\">",
"      Approach to the patient with facial erythema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11943?source=related_link\">",
"      Clinical features and diagnosis of allergic contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24359?source=related_link\">",
"      HIV-associated eosinophilic folliculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=related_link\">",
"      Impetigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=related_link\">",
"      Rosacea: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/28/21961?source=related_link\">",
"      Seborrheic dermatitis in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=related_link\">",
"      Zinc deficiency and supplementation in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_55_9082="Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging";
var content_f8_55_9082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/55/9082/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/55/9082/contributors\">",
"     Charles F Thomas, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/55/9082/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/55/9082/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/55/9082/contributors\">",
"     Arthur T Skarin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/55/9082/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/55/9082/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/55/9082/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial carcinoid tumors are an uncommon group of pulmonary neoplasms that are characterized by neuroendocrine differentiation and relatively indolent clinical behavior. Although originally referred to as bronchial adenomas, these tumors are now recognized as malignant neoplasms because of their potential to metastasize.",
"   </p>",
"   <p>",
"    Like carcinoid (neuroendocrine) tumors at other body sites, bronchial carcinoids are thought to derive from peptide- and amine-producing neuroendocrine cells that have migrated from the embryologic neural crest. Carcinoids can arise at a number of sites throughout the body, including the thymus, lung, gastrointestinal tract, and ovary. The gastrointestinal tract is the most frequently involved site, while lung is the second most common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, classification, clinical features, diagnosis, and staging of bronchial carcinoid tumors will be reviewed here. Treatment and prognosis of bronchial carcinoid tumors, as well as clinical characteristics of carcinoid tumors arising in other sites, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4153?source=see_link\">",
"     \"Bronchial carcinoid tumors: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial carcinoid tumors account for approximately 1 to 2 percent of all lung malignancies in adults and roughly 20 to 30 percent of all carcinoid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Bronchial carcinoids are the most common primary lung neoplasm of children, typically presenting in late adolescence. Typical carcinoids, which are low-grade tumors with a low mitotic rate, are about four times more common than atypical carcinoids, which are intermediate-grade tumors with a higher mitotic rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    necrosis. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Classification, histology, and histochemistry'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Globally, incidence rates range from 0.2 to 2 per 100,000 population per year, and most series suggest a higher incidence in women as compared to men, and in whites as compared to blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/1-3,5-7\">",
"     1-3,5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a nationwide, registry-based Swedish series, the annual incidence rates of bronchial carcinoid among men and women were 0.2 and 1.3 per 100,000 population [",
"      <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In data from the United States Surveillance, Epidemiology and End Results (SEER) database, the annual incidence rates of bronchial carcinoids among white males and white females between 1992 and 1999 were 0.52 and 0.89 per 100,000 population, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/2\">",
"       2",
"      </a>",
"      ]. The corresponding values for black males and black females were 0.39 and 0.57, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although several reports suggest that the incidence of bronchial carcinoid tumors might be increasing over time [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/2,3,7\">",
"     2,3,7",
"    </a>",
"    ], this is at least partly related to the heightened use of advanced medical viewing techniques that detect more asymptomatic tumors.",
"   </p>",
"   <p>",
"    The average age of an adult diagnosed with a typical bronchial carcinoid is 45 years, while in many series, individuals with atypical carcinoids are approximately 10 years older [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether there is an association between bronchial carcinoids and smoking is unclear. In many studies, between one-third and two-thirds of all patients have been smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. Some note a higher prevalence of smoking in patients with atypical as compared to typical carcinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/5,13\">",
"     5,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these reports, causality is not proven, and the epidemiologic data linking smoking with the development of any carcinoid tumor are nowhere near as convincing as they are for bronchogenic cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"     \"Cigarette smoking and other risk factors for lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No other known carcinogens or exposure to environmental agents has been implicated in carcinogenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Inherited predisposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most bronchial NETs are sporadic, although approximately 10 percent may have a hereditary origin. Patients with the autosomal dominant syndrome of multiple endocrine neoplasia type 1 (MEN 1) have a high frequency of endocrine malignancies, and foregut carcinoids (ie, thymus, lung, stomach, or duodenum) arise in approximately 2 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17174?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Definition and genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Familial pulmonary carcinoids not associated with the MEN syndrome have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLASSIFICATION, HISTOLOGY, AND HISTOCHEMISTRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologically, bronchial carcinoids are part of a spectrum of neuroendocrine tumors arising in the lung that are characterized by strikingly different biologic behavior. At one end of the spectrum are typical carcinoid, which are low-grade (well-differentiated), slowly-growing neoplasms that rarely metastasize to extrathoracic structures. At the other end of the spectrum are the high-grade (poorly differentiated) neuroendocrine carcinomas, as typified by small cell lung cancer (SCLC), which behave aggressively, with rapid tumor growth and early distant dissemination. The biologic behavior of atypical carcinoids is intermediate between typical carcinoids and SCLC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite their heterogeneous clinical behavior, lung tumors with neuroendocrine differentiation share certain morphologic and biochemical characteristics. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The capacity to synthesize neuropeptides",
"     </li>",
"     <li>",
"      The presence of submicroscopic cytoplasmic dense core (neuroendocrine) granules, which can be visualized by electron microscopy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     WHO classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification of pulmonary neuroendocrine tumors has been the subject of considerable controversy, and there are multiple competing and confusing classification schemes. In the 2004 World Health Organization (WHO) classification, the spectrum of neuroendocrine tumors of the lung ranges from hyperplastic neuroendocrine cell lesions (carcinoid tumorlets and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia [DIPNECH]) to the high-grade small cell (SCLC) and large cell neuroendocrine tumors (",
"    <a class=\"graphic graphic_table graphicRef50502 \" href=\"UTD.htm?13/32/13836\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link\">",
"     \"Pathology of lung malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical low-grade bronchial carcinoids are composed of cytologically bland cells containing regular round to oval nuclei with finely dispersed chromatin and inconspicuous small nucleoli. The cells are usually polygonal in shape and are arranged in distinct organoid, trabecular, or insular growth patterns with a delicate vascular stroma (",
"    <a class=\"graphic graphic_picture graphicRef81750 graphicRef53833 \" href=\"UTD.htm?33/19/34106\">",
"     picture 1A-B",
"    </a>",
"    ). Mitotic figures are scarce (&lt;2 per 10 high-powered fields [HPF]), and necrosis is not seen.",
"   </p>",
"   <p>",
"    Peripheral typical carcinoids have a prominent spindle cell growth pattern, and up to 75 percent have foci of neuroendocrine cell hyperplasia (DIPNECH)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tumorlets (carcinoid foci smaller than 5 mm in diameter) in the adjacent lung parenchyma. Coexpression of these preinvasive neuroendocrine cell lesions does not seem to affect prognosis, although the number of series with long-term follow-up is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link&amp;anchor=H21#H21\">",
"     \"Pathology of lung malignancies\", section on 'DIPNECH and carcinoid tumorlets'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histologic criteria for intermediate-grade atypical carcinoids include the presence of carcinoid morphology and either necrosis (",
"    <a class=\"graphic graphic_picture graphicRef59297 graphicRef81703 \" href=\"UTD.htm?37/12/38090\">",
"     picture 2A-B",
"    </a>",
"    ) or 2 to 10 mitoses per 10 HPF. Cytologic atypia is also characteristic but insufficiently diagnostic in the absence of these features. However, at the individual patient level, none of these features enables a reliable prediction of clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/18\">",
"     18",
"    </a>",
"    ]. Compared with typical carcinoids, atypical carcinoids present more often with hilar or mediastinal nodal metastases (20 to 60 percent versus 4 to 27 percent), and they have a higher recurrence rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4153?source=see_link&amp;anchor=H1143201178#H1143201178\">",
"     \"Bronchial carcinoid tumors: Treatment and prognosis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A detailed discussion of the pathology of neuroendocrine lung tumors is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link&amp;anchor=H20#H20\">",
"     \"Pathology of lung malignancies\", section on 'Non-small cell neuroendocrine tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Immunohistochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most carcinoids can be tentatively identified on routine light microscopy. Histologic staining patterns for secreted products and certain cytoplasmic proteins provide confirmatory support for the diagnosis.",
"   </p>",
"   <p>",
"    Historically, one of the most important was silver staining. Like other foregut carcinoids, bronchial carcinoids take up silver but do not reduce it (argyrophilic reaction); other carcinoids both take up and reduce silver (argentaffin reaction) (",
"    <a class=\"graphic graphic_table graphicRef56015 \" href=\"UTD.htm?17/7/17531\">",
"     table 2",
"    </a>",
"    ). More recently, immunohistochemical identification of secreted and cytoplasmic products such as synaptophysin, neuron-specific enolase (NSE), and chromogranin has now replaced silver staining as the most reliable method to confirm neuroendocrine differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Presenting signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of tumors arise in the proximal airways, and most are symptomatic from an obstructing tumor mass or bleeding due to hypervascularity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients may have a cough or wheeze, hemoptysis, chest pain, or recurrent pneumonia in the same pulmonary segment or lobe due to bronchial obstruction. Due to misdiagnosis, the diagnosis of a bronchial carcinoid is often delayed, and patients may receive several courses of antibiotics to treat recurrent pneumonia before the carcinoid is diagnosed. (See",
"    <a class=\"local\" href=\"#H17352166\">",
"     'Disorders with similar clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Approximately 75 percent of bronchial carcinoids present with an abnormal chest x-ray. Most tumors appear as round or ovoid opacities that range in size from 2 to 5 cm, and may be associated may be a hilar or perihilar mass (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67489 \" href=\"UTD.htm?30/15/30975\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. If a central tumor results in bronchial obstruction, atelectasis and mucoid impaction may be visible radiographically. Cavitation is rare. Pleural effusions are unusual but may occur with postobstructive pneumonia.",
"   </p>",
"   <p>",
"    Approximately one-fourth of cases present in the periphery as an asymptomatic solitary pulmonary nodule (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56183 \" href=\"UTD.htm?5/61/6097\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef77211 \" href=\"UTD.htm?16/26/16800\">",
"     picture 3",
"    </a>",
"    ). These tumors are frequently discovered on a routine chest x-ray, most commonly as a solitary pulmonary nodule. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=see_link\">",
"     \"Diagnostic evaluation and management of the solitary pulmonary nodule\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of the radiographic presentation is discussed below. (See",
"    <a class=\"local\" href=\"#H17352173\">",
"     'Disorders with similar radiographic manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clinical syndromes related to peptide production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial carcinoid tumors are thought to arise from a specialized bronchial cell (the Kulchitsky cell), which belongs to the diffuse system of neuroendocrine cells. These cells, which include the enterochromaffin cells of the gastrointestinal tract (the presumed cell of origin for gastrointestinal carcinoids), have the ability to take up and modify amine precursors like L-DOPA or 5-hydroxytryptophan. As a group, tumors that arise from these cells (eg, carcinoids, Merkel cell carcinomas, pheochromocytomas, medullary thyroid carcinomas, and pancreatic neuroendocrine [islet cell] tumors) have been referred to as amine precursor uptake and decarboxylation (APUD) tumors (or APUDomas). All of these tumors can synthesize, store, and secrete biologically active neuroamines and neuropeptides, many of which can be measured in the blood or urine. (See",
"    <a class=\"local\" href=\"#H17349561\">",
"     'Tumor markers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Carcinoid syndrome and carcinoid crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoid syndrome is caused by systemic release of vasoactive substances such as serotonin and other bioactive amines (",
"    <a class=\"graphic graphic_table graphicRef79329 \" href=\"UTD.htm?34/59/35771\">",
"     table 3",
"    </a>",
"    ). Acute symptoms include cutaneous flushing, diarrhea, and bronchospasm; long-term sequelae of prolonged elevated hormone levels include venous telangiectasias, right-side predominant valvular heart disease, and fibrosis in the retroperitoneum and other sites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12472?source=see_link\">",
"     \"Carcinoid heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bronchial carcinoids produce lesser quantities of serotonin than do midgut carcinoids, accounting for a lower rate of carcinoid syndrome (",
"    <a class=\"graphic graphic_table graphicRef56015 \" href=\"UTD.htm?17/7/17531\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/19\">",
"     19",
"    </a>",
"    ]. Among patients with localized disease (the vast majority of cases of typical carcinoid), carcinoid syndrome is encountered only rarely and with tumors of large size (&gt;5 cm) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/23\">",
"     23",
"    </a>",
"    ]. However, it is encountered in over 80 percent of patients with liver metastases from bronchial carcinoids.",
"   </p>",
"   <p>",
"    When the carcinoid syndrome occurs in the setting of a bronchial carcinoid, symptoms may be atypical, with episodes of flushing and related manifestations that are particularly prolonged",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe and accompanied by other symptoms. These include disorientation, anxiety tremor, periorbital edema, lacrimation, salivation, hypotension, tachycardia, diarrhea, dyspnea, asthma, and edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical features of the carcinoid syndrome\", section on 'Bronchial carcinoid variant syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, biopsy or manipulation of an actively secreting bronchial carcinoid can induce a carcinoid crisis (acute carcinoid syndrome) due to massive systemic release of bioactive mediators [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Patients acutely develop flushing, diarrhea, and bronchoconstriction, along with other severe manifestations, which can include acidosis, severe hypertension or hypotension, tachycardia, or myocardial infarction. The outcome may be fatal.",
"   </p>",
"   <p>",
"    In contrast to other carcinoids (particularly in the setting of extensive liver metastases), the risk of a carcinoid crisis with pulmonary carcinoids is so low that most clinicians do not recommend prophylactic administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    prior to tumor manipulation (biopsy or resection). Nevertheless, all clinicians caring for these patients should be aware of the potential for carcinoid crisis with manipulation of an actively secreting tumor and the life-saving benefits of octreotide in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16888?source=see_link&amp;anchor=H624742810#H624742810\">",
"     \"Treatment of the carcinoid syndrome\", section on 'Prevention and management of carcinoid crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Cushing's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 1 to 2 percent of bronchial carcinoids (both typical and atypical tumors) are associated with Cushing's syndrome due to ectopic production of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/62/2023?source=see_link\">",
"     adrenocorticotropic hormone",
"    </a>",
"    (ACTH) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. Bronchial carcinoid is the most common cause of ectopic ACTH production; other malignant causes include small cell neuroendocrine lung cancer and disseminated neuroendocrine tumors of unknown primary site. (See",
"    <a class=\"local\" href=\"#H17352166\">",
"     'Disorders with similar clinical manifestations'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=see_link\">",
"     \"Overview of the risk factors, pathology, and clinical manifestations of lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41174?source=see_link\">",
"     \"Neuroendocrine cancer of unknown primary site\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with bronchial carcinoid, symptoms of Cushing&rsquo;s syndrome can be the initial reason for seeking medical attention. The onset is usually acute, and hypokalemia is often present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At least some data suggest that ACTH-producing bronchial carcinoids behave more aggressively than do hormonally-quiescent tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. However, others conclude that outcomes are not worse as long as patients undergo complete anatomic resection that includes complete mediastinal lymphadenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Acromegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acromegaly from the ectopic production of growth hormone releasing hormone (GHRH) is a rare manifestation of a bronchial carcinoid [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/33-41\">",
"     33-41",
"    </a>",
"    ]. However, bronchial carcinoid tumors are the most common cause of extrapituitary GHRH secretion. (See",
"    <a class=\"local\" href=\"#H17352166\">",
"     'Disorders with similar clinical manifestations'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43076?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnosis of acromegaly\", section on 'Other causes of acromegaly'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC AND STAGING WORKUP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of bronchial carcinoids present in a manner that is similar to other primary lung malignancies, with cough or hemoptysis, or as an asymptomatic peripheral pulmonary nodule. Computed tomography is the most useful imaging procedure, and the diagnosis is generally confirmed either by bronchoscopic biopsy (for central lesions) or by transthoracic needle biopsy for peripheral lesions. About three-fourths of bronchial carcinoids are centrally located and amenable to bronchoscopic biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=see_link\">",
"     \"Diagnostic evaluation and management of the solitary pulmonary nodule\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=see_link\">",
"     \"Overview of the initial evaluation, treatment and prognosis of lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=see_link\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H17350455\">",
"     'Bronchoscopy and biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17350165\">",
"    <span class=\"h2\">",
"     Staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary carcinoids are generally staged using the TNM classification for bronchogenic lung carcinomas (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/42\">",
"     42",
"    </a>",
"    ]. The modifications provided in the 7th edition of 2010 provide better prognostic stratification than the stage groupings of the 2002 6th edition [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/43\">",
"     43",
"    </a>",
"    ]. Typical carcinoid tumors most commonly present as stage I tumors, while more than one-half of atypical carcinoids are stage II (bronchopulmonary nodal involvement) or III (mediastinal nodal involvement) at presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cross sectional imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to a chest x-ray, CT provides better resolution of tumor extent, location, and the presence or absence of mediastinal adenopathy. CT gives an excellent morphologic characterization of peripheral and especially centrally located carcinoids, which may be purely intraluminal (polypoid configuration), exclusively extraluminal, or more frequently, a mixture of intraluminal and extraluminal components (an \"iceberg\" lesion). CT may also be helpful for differentiating tumor from postobstructive atelectasis or bronchial obstruction-related mucoid impaction.",
"   </p>",
"   <p>",
"    Tumors may have lobulated or irregular borders and punctate or eccentric calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Contrast-enhanced CT scans frequently show marked enhancement due to the vascular nature of the tumors.",
"   </p>",
"   <p>",
"    Between 5 and 20 percent of typical (low-grade) bronchial carcinoids are associated with hilar or mediastinal adenopathy, but lymphadenopathy may represent a local inflammatory reaction. The sensitivity of CT for detecting metastatic hilar or mediastinal nodes is high, but specificity is as low as 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/46\">",
"     46",
"    </a>",
"    ]. In one study, the positive predictive value of CT-detected lymphadenopathy as an indication of nodal metastases was only 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other imaging procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other imaging procedures have a more limited role in patients suspected of having a bronchial carcinoid tumor but are useful in selected patients:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2521600\">",
"    <span class=\"h3\">",
"     Thoracic MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI generally does not provide more information than can be obtained by high-resolution CT, but dynamic contrast-enhanced MRI may be helpful to differentiate a small contrast-enhancing peripheral carcinoid from pulmonary vessels, or to characterize vascular involvement by a centrally located lesion. The scans characteristically show high signal intensity on T2-weighted images and short T1-inversion-recovery images [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Somatostatin receptor scintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 80 percent of typical bronchial carcinoids express somatostatin receptors by immunohistochemistry and may be imaged with radiolabeled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (somatostatin receptor scintigraphy [SRS], Octreoscan) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/19,47,49-52\">",
"     19,47,49-52",
"    </a>",
"    ]. However, specificity is limited because scintigraphy is positive in many other tumors, granulomas, and autoimmune diseases. A smaller number (approximately 60 percent) of atypical carcinoids express somatostatin receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/52\">",
"     52",
"    </a>",
"    ]. However, not all tumors that express somatostatin receptors by immunohistochemistry will be positive on SRS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link&amp;anchor=H12145128#H12145128\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Somatostatin-receptor scintigraphy (OctreoScan)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One benefit of somatostatin receptor scintigraphy (SRS) over other modalities is that it can image the whole body and identify metastatic disease, particularly outside the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/47\">",
"     47",
"    </a>",
"    ]. Although consensus-based guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    and the North American Neuroendocrine Tumor Society (NANETS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/53\">",
"     53",
"    </a>",
"    ]) suggest \"considering\" a preoperative SRS in patients with a bronchial carcinoid, we do not routinely order preoperative SRS for patients with either typical or atypical bronchial carcinoids. Extrathoracic metastatic disease is rare (5 percent in one series of 525 bronchial carcinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/1\">",
"     1",
"    </a>",
"    ]), and in light of recent improvements in cross-sectional imaging, the clinical value of SRS in the initial evaluation of patients with carcinoid tumors (both for primary tumor localization and assessing the extent of metastatic disease) has been called into question [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link&amp;anchor=H5#H5\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Somatostatin receptor scintigraphy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link&amp;anchor=H262522974#H262522974\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Cross-sectional imaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=see_link&amp;anchor=H31868296#H31868296\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\", section on 'Somatostatin-receptor scintigraphy (OctreoScan)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     PET scans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positron emission tomography (PET) scanning with fluorodeoxyglucose (FDG) as a means of identifying a solitary pulmonary nodule as a carcinoid has yielded conflicting results, probably related to the small size of these tumors and the fact that they are often hypometabolic [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/11,55-57\">",
"     11,55-57",
"    </a>",
"    ]. In a retrospective review of 16 patients with surgically resected bronchial carcinoids, preoperative PET detected only 12 (75 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=see_link\">",
"     \"Diagnostic evaluation and management of the solitary pulmonary nodule\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of other PET tracers, such as 11C-L-DOPA and 11C-5-hydroxytryptophan (11C-5-HT), improves sensitivity for imaging neuroendocrine tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/58\">",
"     58",
"    </a>",
"    ]. In a study of 42 patients (including seven bronchial carcinoids), 11C-5-HT PET scanning detected more tumor lesions than somatostatin receptor scintigraphy or CT. The drawback is the short half-life of 20 minutes of the compound, which necessitates a cyclotron adjacent to the imaging facility. Because of this limitation, neither of these compounds is in routine clinical use. These imaging studies are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link&amp;anchor=H7#H7\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Other functional imaging methods'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Liver imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common metastatic site for all carcinoid tumors is the liver. Abdominal CT scan is typically performed to evaluate for liver metastases. CT scans should be performed both before and after the administration of IV contrast (ie, triphasic contrast-enhanced CT), because carcinoid liver metastases are often hypervascular, becoming isodense relative to the liver parenchyma after contrast administration. As a result of its greater sensitivity for liver metastases, some physicians prefer MRI over CT for assessing the status of the liver in patients with carcinoid tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link&amp;anchor=H262522974#H262522974\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Cross-sectional imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, for patients who are thought to have an isolated bronchial carcinoid, neither of these studies is recommended preoperatively. Typical pulmonary carcinoid tumors only rarely metastasize. While atypical carcinoid tumors have a greater tendency to metastasize, the diagnosis is almost never made preoperatively. In the rare patient with a bronchial carcinoid tumor and symptoms of the carcinoid syndrome, liver imaging is appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17349561\">",
"    <span class=\"h2\">",
"     Tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroendocrine tumors such as carcinoids have the ability to synthesize, store, and secrete biologically active neuroamines and neuropeptides, many of which can be measured in the blood or urine.",
"   </p>",
"   <p>",
"    However, as noted above, not all carcinoids secrete high levels of bioactive peptides. In contrast to midgut tumors, foregut carcinoids (including those arising in the lung) generally have low serotonin content (",
"    <a class=\"graphic graphic_table graphicRef56015 \" href=\"UTD.htm?17/7/17531\">",
"     table 2",
"    </a>",
"    ). This is because foregut carcinoids often lack aromatic amino acid decarboxylase and cannot make serotonin and its metabolites (including 5-HIAA) (",
"    <a class=\"graphic graphic_figure graphicRef51368 \" href=\"UTD.htm?12/15/12542\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Clinical syndromes related to peptide production'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although they can produce a variety of other peptides and hormones within the cell (gastrin releasing peptide [bombesin], 5-hydroxytryptophan, and chromogranins), bronchial carcinoids only occasionally secrete bioactive amines other than serotonin. As a result, elevated plasma or urinary hormone levels are rarely detected.",
"   </p>",
"   <p>",
"    For the rare patient in whom carcinoid syndrome is suspected, urinary excretion of 5-HIAA may be elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/46,59\">",
"     46,59",
"    </a>",
"    ], but it is not as sensitive a test as it is in patients with midgut carcinoids. Certain foods and medications can increase urinary 5-HIAA levels and should be avoided during specimen collection (",
"    <a class=\"graphic graphic_table graphicRef79968 \" href=\"UTD.htm?7/54/8043\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=see_link\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bronchial carcinoids occasionally secrete 5-hydroxytryptophan, but assays for 5-hydroxytryptophan are not available in clinical laboratories in the United States. Measurement of urinary serotonin levels may be of value. It is presumed that DOPA decarboxylase in the renal parenchyma converts the 5-hydroxytryptophan to serotonin in these patients, resulting in high levels of urinary serotonin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\", section on 'Biochemical testing for the carcinoid syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum levels of chromogranin A (CgA) are lower with bronchial carcinoids than they are with neuroendocrine tumors at other sites, and they overlap with those seen in patients who have nonmalignant conditions associated with increased CgA levels (",
"    <a class=\"graphic graphic_table graphicRef73287 \" href=\"UTD.htm?40/9/41116\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/60\">",
"     60",
"    </a>",
"    ]. However, measurement of serum CgA levels can be useful to follow disease activity in the setting of advanced or metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/46,59-62\">",
"     46,59-62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link&amp;anchor=H8#H8\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Biochemical monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17350455\">",
"    <span class=\"h2\">",
"     Bronchoscopy and biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;About three-fourths of bronchial carcinoids are centrally located and amenable to biopsy at the time of bronchoscopy. The bronchoscopic appearance is a typically pink to red vascular mass with intact overlying bronchial epithelium. Carcinoids are generally attached to the bronchus by a broad base but can be polypoid and create a ball-valve effect (",
"    <a class=\"graphic graphic_picture graphicRef69974 \" href=\"UTD.htm?4/58/5039\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The bronchoscopic appearance may be sufficiently characteristic for an experienced bronchoscopist to make a presumptive diagnosis, although it is preferable that brushings or biopsy be performed to confirm the diagnosis.",
"   </p>",
"   <p>",
"    Cytologic study of bronchial brushings is more sensitive than sputum cytology, but the diagnostic yield of cytology is low overall (4 to 63 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. The intact bronchial mucosa overlying the carcinoid tumor prevents cells from exfoliating. Furthermore, the cells may be too few in number or benign in cytologic appearance for an accurate diagnosis. The preoperative diagnosis of atypical carcinoid is particularly difficult.",
"   </p>",
"   <p>",
"    Bronchial carcinoids are vascular, and there has been concern for bleeding in the past, particularly after flexible bronchoscopy with biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/66\">",
"     66",
"    </a>",
"    ]. However, in many contemporary series, the incidence of serious bleeding complications during bronchoscopic biopsy is very low [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/5,46,67\">",
"     5,46,67",
"    </a>",
"    ]. The administration of a diluted epinephrine solution before and after biopsy of a suspected endobronchial carcinoid may have reduced the risk of severe bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=see_link\">",
"     \"Flexible bronchoscopy: Equipment, procedure, and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17350054\">",
"    <span class=\"h3\">",
"     Peripheral pulmonary nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;For peripheral carcinoids that present as solitary pulmonary nodules, CT-guided transthoracic needle aspiration is often the initial diagnostic maneuver. The primary risk with this approach is pneumothorax. However, sometimes patients with a solitary pulmonary nodule proceed directly to surgical excision if the likelihood of malignancy is high. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=see_link\">",
"     \"Diagnostic evaluation and management of the solitary pulmonary nodule\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17352159\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17352166\">",
"    <span class=\"h2\">",
"     Disorders with similar clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of a patient with symptoms of bronchial obstruction, hemoptysis or wheezing include (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=see_link\">",
"     \"Overview of the risk factors, pathology, and clinical manifestations of lung cancer\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An obstructing bronchial carcinoma",
"     </li>",
"     <li>",
"      An endobronchial metastasis",
"     </li>",
"     <li>",
"      Reactive airways disease such as asthma",
"     </li>",
"     <li>",
"      Aspirated foreign body",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For the rare patient who presents with carcinoid syndrome (cutaneous flushing, diarrhea, with or without bronchospasm), the differential diagnosis includes other causes of flushing, diarrhea, as well as reactive airways disease. In addition, carcinoid tumors arising at other sites, including the gastrointestinal tract (carcinoid syndrome is most common in patients with liver metastases from a small bowel carcinoid) and thymus (which are only rarely associated with carcinoid syndrome), should be considered in the differential diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12857?source=see_link\">",
"     \"Approach to flushing in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=see_link\">",
"     \"Approach to the adult with chronic diarrhea in developed countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=see_link\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/28/21962?source=see_link\">",
"     \"Thymic neuroendocrine (carcinoid) tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of Cushing&rsquo;s syndrome includes exogenous administration of glucocorticoids, primary adrenal disease (adenoma or carcinoma), and a pituitary or non-pituitary ACTH-secreting tumor (which may be benign or malignant). The diagnosis of a carcinoid-related Cushing&rsquo;s syndrome may be difficult because the production of ACTH by bronchial carcinoids can be suppressed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , unlike other tumors that produce ectopic ACTH [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37528?source=see_link&amp;anchor=H4#H4\">",
"     \"Dexamethasone suppression tests\", section on 'Low-dose dexamethasone suppression tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of bronchial carcinoid tumors in patients who present with Cushing's syndrome are small (&lt;2 cm) and may be radiographically occult, making it even more difficult to establish the correct diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/32,69\">",
"     32,69",
"    </a>",
"    ]. High-resolution CT with 1 mm sections may be particularly helpful in such cases to identify the primary tumor (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67489 \" href=\"UTD.htm?30/15/30975\">",
"     image 1",
"    </a>",
"    ). Another option is somatostatin receptor scintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/55/9082/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Other imaging procedures'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The differential diagnosis of acromegaly includes excessive growth hormone secretion from a somatotroph adenoma of the pituitary and other rare causes, including a pituitary somatotroph carcinoma, hypothalamic tumor secreting growth hormone-releasing hormone (GHRH), ectopic secretion of GH by a non-endocrine tumor, and excess growth factor activity (acromegaloidism). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43076?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnosis of acromegaly\", section on 'Other causes of acromegaly'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17352173\">",
"    <span class=\"h2\">",
"     Disorders with similar radiographic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most bronchial carcinoids appear as round or ovoid opacities that may be associated with a hilar or perihilar mass. The differential diagnosis includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary lung carcinoma, both small cell and non-small cell",
"     </li>",
"     <li>",
"      Metastatic tumor involvement",
"     </li>",
"     <li>",
"      Other benign causes of a solitary pulmonary nodule (eg, infectious granuloma, hamartomas, dirofilariasis), or multiple pulmonary nodules (eg, pulmonary arteriovenous malformations, pneumoconioses, abscesses, septic emboli, infection with fungi, flukes, and mycobacteria) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the findings on cross-sectional imaging may favor one diagnosis over another, there are no pathognomonic radiographic findings of a bronchial carcinoid, and tissue sampling is needed to definitively establish the diagnosis. (See",
"    <a class=\"local\" href=\"#H17350455\">",
"     'Bronchoscopy and biopsy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=see_link\">",
"     \"Diagnostic evaluation and management of the solitary pulmonary nodule\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/34/14888?source=see_link\">",
"     \"Differential diagnosis and evaluation of multiple pulmonary nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17352443\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial carcinoid tumors are malignant neoplasms that are characterized by neuroendocrine differentiation and indolent clinical behavior.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bronchial carcinoid tumors account for approximately 1 to 2 percent of all lung malignancies in adults and roughly 20 to 30 percent of all carcinoid tumors. Bronchial carcinoids are the most common primary lung neoplasm of children. Most are sporadic, but approximately 10 percent have some feature suggesting a hereditary origin. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Histologically, bronchial carcinoids are part of a spectrum of neuroendocrine tumors arising in the lung that are characterized by strikingly different biologic behavior; typical bronchial carcinoids, which account for the majority of tumors, are low-grade (well-differentiated), slowly-growing neoplasms that rarely metastasize to extrathoracic structures. At the other end of the spectrum are the high-grade (poorly differentiated) neuroendocrine carcinomas, as typified by small cell lung cancer (SCLC), with aggressive behavior, rapid tumor growth, and early distant dissemination. The biologic behavior of atypical carcinoids is intermediate between typical carcinoids and SCLC. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Classification, histology, and histochemistry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with a bronchial carcinoid have a centrally-located tumor and are symptomatic from the tumor mass with coughing, hemoptysis, wheezing, or a recurrent postobstructive pneumonia. Peripheral lesions present most often present as an asymptomatic solitary pulmonary nodule. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rarely, patients present with symptoms related to peptide hormone production by the tumor. Clinical syndromes may include carcinoid syndrome, Cushing&rsquo;s syndrome, and acromegaly. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical syndromes related to peptide production'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Computed tomography is the most useful imaging procedure, and the diagnosis is generally confirmed either by bronchoscopic biopsy (for central lesions) or by transthoracic needle biopsy for peripheral lesions. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnostic and staging workup'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional preoperative staging studies such as MRI, somatostatin receptor scintigraphy, or hepatic imaging are not indicated routinely. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Other imaging procedures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/1\">",
"      Quaedvlieg PF, Visser O, Lamers CB, et al. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol 2001; 12:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/2\">",
"      Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/3\">",
"      Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001; 92:2204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/4\">",
"      Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008; 113:2655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/5\">",
"      Fink G, Krelbaum T, Yellin A, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 2001; 119:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/6\">",
"      Gatta G, Ciccolallo L, Kunkler I, et al. Survival from rare cancer in adults: a population-based study. Lancet Oncol 2006; 7:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/7\">",
"      Yao JC, Hassan M, Phan A, et al. One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26:3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/8\">",
"      Skuladottir H, Hirsch FR, Hansen HH, Olsen JH. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 2002; 37:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/9\">",
"      Cao C, Yan TD, Kennedy C, et al. Bronchopulmonary carcinoid tumors: long-term outcomes after resection. Ann Thorac Surg 2011; 91:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/10\">",
"      Beasley MB, Thunnissen FB, Brambilla E, et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 2000; 31:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/11\">",
"      Erasmus JJ, McAdams HP, Patz EF Jr, et al. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 1998; 170:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/12\">",
"      Kayser K, Kayser C, Rahn W, et al. Carcinoid tumors of the lung: immuno- and ligandohistochemistry, analysis of integrated optical density, syntactic structure analysis, clinical data, and prognosis of patients treated surgically. J Surg Oncol 1996; 63:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/13\">",
"      Froudarakis M, Fournel P, Burgard G, et al. Bronchial carcinoids. A review of 22 cases. Oncology 1996; 53:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/14\">",
"      Brokx HA, Risse EK, Paul MA, et al. Initial bronchoscopic treatment for patients with intraluminal bronchial carcinoids. J Thorac Cardiovasc Surg 2007; 133:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/15\">",
"      Oliveira AM, Tazelaar HD, Wentzlaff KA, et al. Familial pulmonary carcinoid tumors. Cancer 2001; 91:2104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/16\">",
"      Aubry MC, Thomas CF Jr, Jett JR, et al. Significance of multiple carcinoid tumors and tumorlets in surgical lung specimens: analysis of 28 patients. Chest 2007; 131:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/17\">",
"      Ruffini E, Bongiovanni M, Cavallo A, et al. The significance of associated pre-invasive lesions in patients resected for primary lung neoplasms. Eur J Cardiothorac Surg 2004; 26:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/18\">",
"      Rugge M, Fassan M, Clemente R, et al. Bronchopulmonary carcinoid: phenotype and long-term outcome in a single-institution series of Italian patients. Clin Cancer Res 2008; 14:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/19\">",
"      Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. Cancer 2008; 113:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/20\">",
"      Nessi R, Basso Ricci P, Basso Ricci S, et al. Bronchial carcinoid tumors: radiologic observations in 49 cases. J Thorac Imaging 1991; 6:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/21\">",
"      Abdi EA, Goel R, Bishop S, Bain GO. Peripheral carcinoid tumours of the lung: a clinicopathological study. J Surg Oncol 1988; 39:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/22\">",
"      Jeung MY, Gasser B, Gangi A, et al. Bronchial carcinoid tumors of the thorax: spectrum of radiologic findings. Radiographics 2002; 22:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/23\">",
"      Fischer S, Kruger M, McRae K, et al. Giant bronchial carcinoid tumors: a multidisciplinary approach. Ann Thorac Surg 2001; 71:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/24\">",
"      Karmy-Jones R, Valli&egrave;res E. Carcinoid crisis after biopsy of a bronchial carcinoid. Ann Thorac Surg 1993; 56:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/25\">",
"      Mehta AC, Rafanan AL, Bulkley R, et al. Coronary spasm and cardiac arrest from carcinoid crisis during laser bronchoscopy. Chest 1999; 115:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/26\">",
"      Limper AH, Carpenter PC, Scheithauer B, Staats BA. The Cushing syndrome induced by bronchial carcinoid tumors. Ann Intern Med 1992; 117:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/27\">",
"      Jones JE, Shane SR, Gilbert E, Flink EB. Cushing's syndrome induced by the ectopic production of ACTH by a bronchial carcinoid. J Clin Endocrinol Metab 1969; 29:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/28\">",
"      DeStephano DB, Lloyd RV, Schteingart DE. Cushing's syndrome produced by a bronchial carcinoid tumor. Hum Pathol 1984; 15:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/29\">",
"      Scanagatta P, Montresor E, Pergher S, et al. Cushing's syndrome induced by bronchopulmonary carcinoid tumours: a review of 98 cases and our experience of two cases. Chir Ital 2004; 56:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/30\">",
"      Shrager JB, Wright CD, Wain JC, et al. Bronchopulmonary carcinoid tumors associated with Cushing's syndrome: a more aggressive variant of typical carcinoid. J Thorac Cardiovasc Surg 1997; 114:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/31\">",
"      Pass HI, Doppman JL, Nieman L, et al. Management of the ectopic ACTH syndrome due to thoracic carcinoids. Ann Thorac Surg 1990; 50:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/32\">",
"      Deb SJ, Nichols FC, Allen MS, et al. Pulmonary carcinoid tumors with Cushing's syndrome: an aggressive variant or not? Ann Thorac Surg 2005; 79:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/33\">",
"      Filosso PL, Donati G, Rena O, Oliaro A. Acromegaly as manifestation of a bronchial carcinoid tumour. Asian Cardiovasc Thorac Ann 2003; 11:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/34\">",
"      Scheithauer BW, Carpenter PC, Bloch B, Brazeau P. Ectopic secretion of a growth hormone-releasing factor. Report of a case of acromegaly with bronchial carcinoid tumor. Am J Med 1984; 76:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/35\">",
"      Dabek FT. Bronchial carcinoid tumour with acromegaly in two patients. J Clin Endocrinol Metab 1974; 38:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/36\">",
"      Carroll DG, Delahunt JW, Teague CA, et al. Resolution of acromegaly after removal of a bronchial carcinoid shown to secrete growth hormone releasing factor. Aust N Z J Med 1987; 17:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/37\">",
"      Garcia-Luna PP, Leal-Cerro A, Montero C, et al. A rare cause of acromegaly: ectopic production of growth hormone-releasing factor by a bronchial carcinoid tumor. Surg Neurol 1987; 27:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/38\">",
"      Athanassiadi K, Exarchos D, Tsagarakis S, Bellenis I. Acromegaly caused by ectopic growth hormone-releasing hormone secretion by a carcinoid bronchial tumor: a rare entity. J Thorac Cardiovasc Surg 2004; 128:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/39\">",
"      Osella G, Orlandi F, Caraci P, et al. Acromegaly due to ectopic secretion of GHRH by bronchial carcinoid in a patient with empty sella. J Endocrinol Invest 2003; 26:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/40\">",
"      Bhansali A, Rana SS, Bhattacharya S, et al. Acromegaly: a rare manifestation of bronchial carcinoid. Asian Cardiovasc Thorac Ann 2002; 10:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/41\">",
"      Zatelli MC, Maffei P, Piccin D, et al. Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid. J Clin Endocrinol Metab 2005; 90:2104.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.253.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/43\">",
"      Travis WD, Giroux DJ, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2008; 3:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/44\">",
"      Magid D, Siegelman SS, Eggleston JC, et al. Pulmonary carcinoid tumors: CT assessment. J Comput Assist Tomogr 1989; 13:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/45\">",
"      Zwiebel BR, Austin JH, Grimes MM. Bronchial carcinoid tumors: assessment with CT of location and intratumoral calcification in 31 patients. Radiology 1991; 179:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/46\">",
"      Divisi D, Crisci R. Carcinoid tumors of the lung and multimodal therapy. Thorac Cardiovasc Surg 2005; 53:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/47\">",
"      Granberg D, Sundin A, Janson ET, et al. Octreoscan in patients with bronchial carcinoid tumours. Clin Endocrinol (Oxf) 2003; 59:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/48\">",
"      Douek PC, Simoni L, Revel D, et al. Diagnosis of bronchial carcinoid tumor by ultrafast contrast-enhanced MR imaging. AJR Am J Roentgenol 1994; 163:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/49\">",
"      Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990; 50:5969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/50\">",
"      Weiss M, Yellin A, Husza'r M, et al. Localization of adrenocorticotropic hormone-secreting bronchial carcinoid tumor by somatostatin-receptor scintigraphy. Ann Intern Med 1994; 121:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/51\">",
"      Yellin A, Zwas ST, Rozenman J, et al. Experience with somatostatin receptor scintigraphy in the management of pulmonary carcinoid tumors. Isr Med Assoc J 2005; 7:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/52\">",
"      Righi L, Volante M, Tavaglione V, et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Ann Oncol 2010; 21:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/53\">",
"      Phan AT, Oberg K, Choi J, et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas 2010; 39:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/54\">",
"      Reidy-Lagunes DL, Gollub MJ, Saltz LB. Addition of octreotide functional imaging to cross-sectional computed tomography or magnetic resonance imaging for the detection of neuroendocrine tumors: added value or an anachronism? J Clin Oncol 2011; 29:e74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/55\">",
"      Daniels CE, Lowe VJ, Aubry MC, et al. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest 2007; 131:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/56\">",
"      Rege SD, Hoh CK, Glaspy JA, et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 1993; 72:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/57\">",
"      Chong S, Lee KS, Kim BT, et al. Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. AJR Am J Roentgenol 2007; 188:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/58\">",
"      Orlefors H, Sundin A, Garske U, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005; 90:3392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/59\">",
"      Granberg D, Eriksson B, Wilander E, et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol 2001; 12:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/60\">",
"      Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007; 25:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/61\">",
"      Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 2004; 60:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/62\">",
"      Modlin IM, Gustafsson BI, Moss SF, et al. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010; 17:2427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/63\">",
"      Aron M, Kapila K, Verma K. Carcinoid tumors of the lung: a diagnostic challenge in bronchial washings. Diagn Cytopathol 2004; 30:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/64\">",
"      Okike N, Bernatz PE, Woolner LB. Carcinoid tumors of the lung. Ann Thorac Surg 1976; 22:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/65\">",
"      Nguyen GK. Cytopathology of pulmonary carcinoid tumors in sputum and bronchial brushings. Acta Cytol 1995; 39:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/66\">",
"      Todd TR, Cooper JD, Weissberg D, et al. Bronchial carcinoid tumors: twenty years' experience. J Thorac Cardiovasc Surg 1980; 79:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/67\">",
"      Kurul IC, Top&ccedil;u S, Ta��tepe I, et al. Surgery in bronchial carcinoids: experience with 83 patients. Eur J Cardiothorac Surg 2002; 21:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/68\">",
"      Malchoff CD, Orth DN, Abboud C, et al. Ectopic ACTH syndrome caused by a bronchial carcinoid tumor responsive to dexamethasone, metyrapone, and corticotropin-releasing factor. Am J Med 1988; 84:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/69\">",
"      Vincent JM, Trainer PJ, Reznek RH, et al. The radiological investigation of occult ectopic ACTH-dependent Cushing's syndrome. Clin Radiol 1993; 48:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/55/9082/abstract/70\">",
"      Tsagarakis S, Christoforaki M, Giannopoulou H, et al. A reappraisal of the utility of somatostatin receptor scintigraphy in patients with ectopic adrenocorticotropin Cushing's syndrome. J Clin Endocrinol Metab 2003; 88:4754.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4883 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4D6C774D8A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_55_9082=[""].join("\n");
var outline_f8_55_9082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17352443\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Inherited predisposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLASSIFICATION, HISTOLOGY, AND HISTOCHEMISTRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      WHO classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Presenting signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clinical syndromes related to peptide production",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Carcinoid syndrome and carcinoid crisis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSTIC AND STAGING WORKUP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17350165\">",
"      Staging system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cross sectional imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other imaging procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2521600\">",
"      - Thoracic MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Somatostatin receptor scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - PET scans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Liver imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17349561\">",
"      Tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17350455\">",
"      Bronchoscopy and biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17350054\">",
"      - Peripheral pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17352159\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17352166\">",
"      Disorders with similar clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17352173\">",
"      Disorders with similar radiographic manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17352443\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4883\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4883|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/15/30975\" title=\"diagnostic image 1\">",
"      Typical carcinoid CXR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/61/6097\" title=\"diagnostic image 2\">",
"      Typical carcinoid RML CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4883|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/15/12542\" title=\"figure 1\">",
"      Tryptophan and serotonin metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4883|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/44/36552\" title=\"picture 1A\">",
"      Carcinoid lung low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/16/6407\" title=\"picture 1B\">",
"      Oncocytic oxyphilic carcinoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/11/11448\" title=\"picture 2A\">",
"      Atypical carcinoid necrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/56/3977\" title=\"picture 2B\">",
"      Atypical carcinoid lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/26/16800\" title=\"picture 3\">",
"      Typical carcinoid gross app",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/58/5039\" title=\"picture 4\">",
"      Typ carcinoid bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4883|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/32/13836\" title=\"table 1\">",
"      WHO neuroendo tum lung 2004",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/7/17531\" title=\"table 2\">",
"      Characteristics of carcinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/59/35771\" title=\"table 3\">",
"      Products of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/41/37533\" title=\"table 4\">",
"      Lung cancer TMN staging 7th edition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/54/8043\" title=\"table 5\">",
"      Interference with 5 HIAA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/9/41116\" title=\"table 6\">",
"      Conditions associated with elevated chromogranin A",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12857?source=related_link\">",
"      Approach to flushing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=related_link\">",
"      Approach to the adult with chronic diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4153?source=related_link\">",
"      Bronchial carcinoid tumors: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12472?source=related_link\">",
"      Carcinoid heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=related_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=related_link\">",
"      Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37528?source=related_link\">",
"      Dexamethasone suppression tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43076?source=related_link\">",
"      Diagnosis of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=related_link\">",
"      Diagnosis of the carcinoid syndrome and tumor localization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=related_link\">",
"      Diagnostic evaluation and management of the solitary pulmonary nodule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/34/14888?source=related_link\">",
"      Differential diagnosis and evaluation of multiple pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=related_link\">",
"      Establishing the cause of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=related_link\">",
"      Flexible bronchoscopy: Equipment, procedure, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17174?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Definition and genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41174?source=related_link\">",
"      Neuroendocrine cancer of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=related_link\">",
"      Overview of the initial evaluation, treatment and prognosis of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=related_link\">",
"      Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=related_link\">",
"      Pathobiology and staging of small cell carcinoma of the lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=related_link\">",
"      Pathology of lung malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/28/21962?source=related_link\">",
"      Thymic neuroendocrine (carcinoid) tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16888?source=related_link\">",
"      Treatment of the carcinoid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_55_9083="Features esophageal chest pain";
var content_f8_55_9083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features found more frequently in patients with esophageal chest pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Pain provoked by swallowing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain provoked by postural changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain palliated by antacids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        An inconsistent relationship to exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Substernal chest pain that does not radiate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequent episodes of spontaneous pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nocturnal pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe onset of pain, continuing as a background ache for several hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain associated with heartburn and regurgitation of acid into the mouth",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Davies, HA, Jones, DB, Rhodes, J, Newcombe, RG, J Clin Gastroenterology 1985; 7:477.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_55_9083=[""].join("\n");
var outline_f8_55_9083=null;
var title_f8_55_9084="Risk for high altitude illness";
var content_f8_55_9084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk for high altitude illness",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk of HAI",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Low",
"       </td>",
"       <td>",
"        No prior history of altitude illness and planning ascent to &lt;2800 m",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Taking two days or more to arrive at 2500 to 3000 m from low altitude",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascending no more than 500 m/day (sleeping altitude) once over 2500 m",
"        <strong>",
"         and",
"        </strong>",
"        taking one extra day to acclimatize for every additional 1000 m of ascent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Moderate",
"       </td>",
"       <td>",
"        Prior history of AMS and ascending to 2500 to 2800 m in less than two days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No history of AMS and ascending to 2800 m or higher in less than two days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascending &gt;500 m/day (increase in sleeping elevation) at altitudes above 3000 m",
"        <strong>",
"         with",
"        </strong>",
"        one extra day for acclimatization for every additional 1000 m of ascent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        High",
"       </td>",
"       <td>",
"        History of severe altitude illness (HACE, HAPE)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of AMS and ascending to 2800 m or higher in less than two days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascending over 3500 m in less than two days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascending &gt;500 m/day (increase in sleeping elevation) above 3000 m without extra days for acclimatization; rapid guided ascents (eg, Mt. Kilimanjaro in &lt;7 days)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persons with medical conditions predisposing to altitude illness",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Notes:",
"    <br>",
"     Altitudes listed refer to the altitude at which the person sleeps.",
"     <br>",
"      Ascent is assumed to begin at low altitude (&lt;1200m).",
"      <br>",
"       Risk categories are for unacclimatized persons.",
"       <div class=\"footnotes\">",
"        AMS: acute mountain sickness; HACE: high altitude cerebral edema; HAPE: high altitude pulmonary edema; m: meters.",
"       </div>",
"       <div class=\"reference\">",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_55_9084=[""].join("\n");
var outline_f8_55_9084=null;
var title_f8_55_9085="Diagnosis posttraumatic stress disorder";
var content_f8_55_9085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for posttraumatic stress disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Criterion A: The",
"person has been exposed to a traumatic event in which both of the",
"following were present:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. The person experienced, witnessed or was confronted",
"with an event or events that involved actual or threatened death or serious injury,",
"or a threat to the physical integrity of self or others.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. The person's response involved intense fear,",
"helplessness or horror. Note: in children this may be expressed instead by disorganized",
"or agitated behavior.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Criterion B: The",
"traumatic event is persistently reexperienced in one (or more) of the",
"following ways:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Recurrent and intrusive distressing recollections of",
"the event, including images, thoughts, or perceptions. Note: in young children,",
"repetitive play may occur in which themes or aspects of the trauma are expressed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Recurrent distressing dreams of the event. Note: in",
"children there may be frightening dreams without recognizable content.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Acting or feeling as if the traumatic event were",
"recurring (including a sense of reliving the experience, illusions, hallucinations and",
"dissociative flashback episodes, including those that occur on wakening or when intoxicated).",
"Note: in young children trauma-specific reenactment may occur.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Intense psychological distress and/or physiological",
"reactivity on exposure to internal or external cues that symbolize or resemble an aspect",
"of the traumatic event.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Criterion C:",
"Persistent avoidance of stimuli associated with the trauma and numbing",
"of general responsiveness (not present before the trauma), as indicated",
"by three (or more) of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Efforts to avoid thoughts, feelings or conversations",
"associated with the trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Efforts to avoid activities, places or people that",
"arouse recollections of the trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Inability to recall an important aspect of the trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Markedly diminished interest in participating in",
"significant activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Feeling detached or estranged from others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Restricted range of effect (eg, unable to have",
"loving feelings)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Sense of a foreshortened future (eg, does not expect",
"to have a career, marriage, children, or a normal life span)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Criterion D:",
"Persistent symptoms of increased arousal (not present before trauma),",
"as indicated by two (or more) of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Difficulty falling or staying asleep",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Irritability or outbursts of anger",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Difficulty concentrating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Hypervigilance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Exaggerated startle response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Criterion E:",
"Duration of the disturbance (symptoms in criteria B, C, and D) is more",
"than one month.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Criterion F:",
"Disturbance causes clinically significant distress or impairment in",
"social, occupational, or other important areas of functioning.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Specify if:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute: if duration of symptoms is less than three months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic: if duration of symptoms is three months or more",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        With delayed onset: if onset of symptoms is at least",
"six months after the stressor",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association, Washington, DC 1994.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_55_9085=[""].join("\n");
var outline_f8_55_9085=null;
var title_f8_55_9086="Pacemaker congenital CHB";
var content_f8_55_9086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Timing of pacemaker implantation according to age at diagnosis of congenital CHB",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 294px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 102 cases of congenital complete heart block (CHB), most patients ultimately had a pacemaker inserted, regardless of the time of onset of the syndrome. By 20 years of age, only 11 percent of neonatal and 12 percent of childhood cases had not required pacemaker implantation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Jaeggi, ET, Hamilton, RM, Silverman, ED, et al, J Am Coll Cardiol 2002; 39:130.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_55_9086=[""].join("\n");
var outline_f8_55_9086=null;
var title_f8_55_9087="Gestational sac TAUS";
var content_f8_55_9087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gestational sac (transabdominal ultrasound)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 244px; height: 226px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transabdominal sagittal image shows a fluid collection in the uterus (G) suggestive of a gestational sac.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tejas S Mehta, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_55_9087=[""].join("\n");
var outline_f8_55_9087=null;
               